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ABSTRACT 
Renpeng Liu: Chemoenzymatic synthesis of heparan sulfate  
(Under the direction of Jian Liu, Ph.D.) 
 
Heparan sulfate (HS) participates in a variety of biological functions and has been 
exploited for its ability to be utilized as a HS-based drug.  Chemical synthesis of HS remains 
extremely challenging.  Previous research has proven the feasibility of using a HS enzyme-
based approach to synthesize HS structures with unique biological activities.  Our central 
hypothesis is that all subsequent modifications following N-sulfation during HS biosynthesis 
are governed by the number and position of the GlcNS residue.  In this dissertation, a 
fluorous affinity tag-assisted chemoenzymatic synthesis technique has been developed to 
build a HS octasaccharide library with defined N-sulfo glucosamine (GlcNS) positions.  The 
HS backbone was synthesized by heparosan biosynthetic enzymes. N-acetyl glucosaminyl 
transferase from E.coli K5 (KfiA) was used to transfer either GlcNAc or GlcNTFA (N-
trifluoroacetylglucosamine) residues to the growing chain. Heparosan synthase from 
pasteurella (PmHS2) was used to transfer the GlcUA residues.  A selective de-
trifluoroacetylation was performed because under these conditions, the GlcNTFA is labile 
and will be converted to glucosamine (GlcNH2) while the GlcNAc residue remains intact. 
The resultant GlcNH2 is then converted to a GlcNS residue by N-sulfotransferase (NST).   N-
sulfo-6-O-sulfo HS backbones with different 6-O-sulfation patterns and different sizes were 
 ii
also prepared. Furthermore, we prepared oligosaccharide capable of binding to antithrombin 
(AT), which correlates to HS anticoagulant activity. In this study, an AT-binding 
dodecasaccharide was prepared and its structure was proven.  The continuation of this 
dissertation will allow us to not only investigate enzymatic approaches to synthesize HS-
based anticoagulant drugs, but also develop a general method for synthesizing structurally 
defined HS oligosaccharides that could aid in the discovery of novel HS-based therapeutic 
agents.
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Chapter I.  INTRODUCTION 
 
Section 1. Structure of heparan sulfate 
Heparan sulfate (HS) is a highly sulfated polysaccharide that represents a unique class 
of natural products.  Heparin is a special type of HS synthesized within mast cells.  It was 
discovered in 1918 (1) and has been widely used as an anticoagulant drug for decades.  
HS/heparin consists of 50 to 100 disaccharide units carrying sulfo groups.  HS has an average 
molecular weight of about 30 kDa ranging from 5 to 50 kDa while heparin has an average 
molecular weight of 12 kDa ranging from 5-40 kDa (2-4).  HS/heparin belongs to the 
glycosaminoglycan family.  Depending on the structures of the disaccharide repeating units, 
glycosaminoglycans are classified as HS, heparin, chondroitin sulfate (CS), dermatan sulfate 
(DS), keratan sulfate (KS) and hyaluronic acid (HA).  HS and heparin consist of highly 
sulfated repeating disaccharide units of 1→4 linked glucosamine (GlcN) and glucuronic 
(GlcUA)/iduronic acid (IdoUA) (Figure 1).  CS and DS consist of sulfated repeating 
disaccharide units of 1→3 linked N-acetylgalactosamine (GalNAc) and GlcUA/IdoUA, and 
KS consists of sulfated repeating disaccharide units of 1→3 linked galactose (Gal) and N-
acetylglucosamine (GlcNAc).  HA consists of repeating disaccharide units of 1→3-linked 
GlcNAc and GlcUA and has no sulfo groups. 
 
  
 
Fig 1.  Disaccharide repeating units of HS and heparin.  Sulfation (R= -SO3) at Carbon 6 (known as 6-O-
sulfated glucosamine, GlcN6S) of glucosamine is common.  Sulfation (R’= -SO3) at Carbon 2 of iduronic 
acid (known as 2-O-sulfated iduronic acid, IdoUA2S) is common.  Sulfation at Carbon 3 of glucosamine 
(known as 3-O-sulfated glucosamine, GlcN3S) is rare.  Both N-acetylated (R’’=acetyl, GlcNAc) and N-
sulfated (R’’= -SO3, GlcNS) are common.  N-unsubstituted glucosamine (R’’= -H, GlcNH2) is a low 
abundant component. IdoUA (2S) is presented in both 1C4 and 2S0 conformation. Both conformations are 
presented (13). 
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 HS is widely expressed on the cell surface and within the extracellular matrix on HS 
proteoglycans (HSPGs, which contain a core protein and polysaccharide side chains).  
HSPGs are involved in numerous biological processes, including blood coagulation, wound 
healing, embryonic development, and regulation of tumor growth, as well as assisting viral 
and bacterial infections (5-13).  HS polysaccharides play an essential role in HSPGs 
functions.  The wide ranges of biological functions of HS attract considerable interest in 
exploiting HS-based anticoagulant, antiviral and anticancer drugs.  
The majority of glucosamine residues are either N-acetylated (GlcNAc) or N-sulfated 
(GlcNS) (14-16).  However, up to 7% of the glucosamine residues in HS are present as N-
unsubstituted glucosamine (GlcNH2) which may play an important biological role (17).  For 
example, it is known that the GlcNH2 unit is involved in the binding of herpes simplex virus 
1’s (HSV-1) glycoprotein D (gD) (11, 18).  The 6-O-sulfo glucosamine (GlcN6S) and 2-O-
sulfo iduronic acid (IdoUA2S) units are common sulfated monosaccharides, and these units 
play critical roles in binding to fibroblast growth factors (FGFs), fibroblast growth factor 
receptors (FGFRs) (19) and platelet factor 4 (PF4) (20).  3-O-sulfo glucosamine is a rare 
component of HS and plays an important role in binding to antithrombin (AT) (3) as well as 
binding to HSV-1 gD (21).  The distribution of different sulfo groups determines the 
biological function of HS.  Although the overall structures of heparin and HS are similar; 
heparin has a higher content of IdoUA and more sulfo groups per disaccharide unit (3, 4).  
HS contains 0.6 sulfo groups per disaccharide unit, and 40% uronic acid of HS is iduronic, 
while heparin contains 2.6 sulfo groups per disaccharide unit and 90% uronic acid of heparin 
is iduronic (3, 4).  In fact, heparin has the most negative charge of all glycosaminoglycans. 
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 Section 2. Biological function of heparan sulfate 
Anticoagulant activity 
Heparin has remained the main anticoagulant drug on the market since it was 
introduced in the 1930s (2).  The coagulation cascade consists of a series of proteases and 
their precursors. The anticoagulant action of heparin is due to the activation of the serine 
protease inhibitor AT.  The AT/heparin complex inhibits the activity of factor Xa and 
thrombin (or named as factor IIa), two key proteases in controlling the blood coagulation 
cascade (Figure 2).  The advantages of heparin as an anticoagulant drug include the 
following: heparin is the only drug can inhibit both factor Xa and thrombin activities, heparin 
has a fast anticoagulant response, and excessive anticoagulant activity can be reversed by 
protamine (3).  
Heparin is an exclusive product of mast cells, and is released during degranulation of 
mast cells.  Therefore, HS, rather than heparin, is considered to be the “natural anticoagulant” 
in humans.  Pharmaceutical grade heparin is derived from slaughtered domesticated animal 
tissues such as the porcine intestines.  The purity of heparin heavily depends on the quality of 
the pig resource (13).  It is estimated that 30-40 tons of heparin are prepared each year 
worldwide from 400 to 700 million pigs (22).  The majority is from China.  
Heparin’s complex structure causes many of the unwanted side effects of heparin, 
including hemorrhaging and heparin-induced thrombocytopenia (HIT) (23).  Furthermore, 
since heparin supply chain is long, it could be contaminated by human factors.  Most recently, 
a contaminated heparin drug made by Scientific Protein Labs (SPL) caused severe side 
effects including life-threatening anaphylactic reactions resulting in abnormally low blood 
pressure, difficultly breathing and occasional vomiting (13, 24).  Hundreds of patients 
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 worldwide have suffered the severe reactions linked to this contaminated heparin and this 
accident has led to 81 deaths.  This accident resulted in a major heparin recall in the USA, 
countries of the European Union and Japan.  Oversulfated chondroitin sulfate (OSCS) was 
identified as the contaminant in heparin (25, 26), and it is believed to have been intensionally 
added for illegal profits. This tragic event suggested that the heparin supply chain is 
vulnerable.  Thus, a synthetic heparin that can be manufactured in a confined facility remains 
a high priority. The cofined facility can increase the purity and decrease the chances of 
contamination. 
 
Intrinsic pathway activation Extrinsic pathway activation
II IIa
Antithrombin
Inhibit
Inhibit
(thrombin)
Fibrinogen Fibrin
Clot
XII XIIa VIIVIIa
XI XIa
IX IXa
X
Tissue factor Trauma
Trauma
XXa
Heparin
 
 
Fig 2. Coagulation cascade. The anticoagulant action of heparin is due to the activation of the serine 
protease inhibitor antithrombin (AT). 
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 Assisting virus infection 
In order to establish an infection, a virus must first make close contact with the host 
cell.  Since HSPGs are widely expressed on the human cell surface, it is not surprising that 
HS could function as docking and/or receptor sites for different viruses to attach to and/or 
invade host cell.  HSV-1, human immunodeficiency virus (HIV) and hepatitis virus C (HCV) 
are known to utilize HS to establish the infection (11).  Therefore, the mechanism of HS-
involvement in viral interaction with host cells has attracted considerable interest from both 
scientific and pharmaceutical communities.  
The involvements of HS in HSV-1 and HIV infections are the most thoroughly 
studied.  HSV-1 is a widespread virus which can cause facial mucocutanous lesions, keratitis, 
and occasionally, life-threatening encephalitis. The involvement of cell surface HS in HSV-1 
infection was discovered in 1989 (27).  It is believed that HSV-1 first attaches to target cells 
through an interaction between its viral envelope glycoprotein C (gC), or in some cases of 
glycoprotein B (gB) and HS on the surface of host cells (11, 21).  Structural analysis of HS 
involvement in gC binding indicated that a saccharide sequence containing IdoUA2S and 
GlcNS(or Ac)6S is required for this interaction.  Once contact is established, the binding of 
viral envelope protein gD and the cell surface entry receptors triggers fusion between viral 
particles and their target cells, permitting the viral particles to penetrate the target cell 
membrane (21).  Studies indicated that the 3-O-sulfo glucosamine of HS plays an important 
role in binding to HSV-1 gD.  It is important to note that the 3OST1-modified HS does not 
bind to gD while 3OST3 and 3OST5-modified HS binds to gD, suggesting that 3-O-sulfated 
HS involved in the HSV-1 infection contains a specific 3-O-sulfation pattern (11, 28-30). 
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 Several lines of research revealed that HS may play multiple roles in assisting HIV 
infection (11).  First, it has been known for a long time that HS interacts with HIV envelop’s 
glycoprotein gp120, the key viral protein for cell entry, and that this interaction facilitates the 
binding of HIV to host cells (31).  HS binding to gp120 has been localized on the V3 loop.  A 
V3 loop is a major epitope of gp120 which carriess variable positive charges.  Although the 
V3 loop is not involved in the initial gp120-CD4 binding, it plays an essential role in 
subsequent steps that lead to membrane fusion for viral entry (4, 32 and 33).  Recent studies 
showed other domains, including the cryptic and CD4-induced coreceptor binding surface, 
contribute to gp120-HS binding (34).  Structural selectivity studies of heparin involved in the 
binding of gp120 and CD4 have been carried out.  These studies showed O-sulfation, 
especially 6-O-sulfation, and N-substitution (N-sulfation or acetylation) are both essential for 
binding.  Also, the minimum size of gp-120 binding heparin is a decasaccharide (4, 35).  In 
addition to the role of facilitating initial binding of HIV to the target cell, HS promotes the 
spreading of HIV.  A recent study shows HIV relies on HS to attach to the surface of sperm 
and these HIV viruses are transmitted to physiological target cells of HIV, such as dendritic 
cells, T cells and macrophages (36).  Finally, HS facilitates the internalization of HIV 
transactivator protein, Tat, an etiologic agent of AIDS.  Tat is released from HIV infected 
cells, and internalized Tat causes damage to the cells and tissues (11, 37-39).  It is found that 
Tat binds to heparin or HS, and minimum size of the Tat binding domain is a hexasaccharide.  
The binding affinity increases with increasing oligosaccharide size, and about eighteen 
saccharide residues are required to match the full affinity of heparin (4, 11 and 40).  
Therefore, HS and heparin could be a potential multi-target agent in the therapy and 
prevention of HIV infection. 
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 Stimulating cell proliferation 
The FGFs are a family of growth factors involved in angiogenesis, wound healing, and 
embryonic development (4, 19).  A total of 22 different isoforms of FGF have been reported 
(41).  FGFs are key players in proliferation and differentiation of a wide variety of cells and 
tissues.  The FGF signaling pathway is initiated by the binding of FGF to its receptor on the 
cell surface, triggering the dimerization of FGFR and downstream phosphorylation/activation 
of enzymes (42).  It is well known that FGFs are heparin-binding proteins and interactions 
with cell-surface associated HS proteoglycans have been shown to be essential for FGF 
signal transduction.  The FGF, FGFR and HS interaction has been elucidated by crystal 
structures.  The crystal structure of a dimeric ternary complex of 2:2:2 FGF-2, a heparin 
decasaccharide and FGFR-1 demonstrated that heparin makes contact with both FGF-2 and 
FGFR-1 in each FGF-FGFR complex to stabilize FGF-FGFR binding.  The FGFR-1 of the 
adjacent FGF-FGFR complex also makes contact with heparin to promote FGFR 
dimerization (4, 43).  In contrast, the crystal structure of a complex of 2:2:1 FGF-1, FGFR-2 
and a heparin decasacchride indicated a different dimerization pattern.  In this complex, the 
heparin molecule links to two FGF-1 ligands into a dimer.  The 2:1 FGF-1 heparin complex 
acts as a bridge between the two FGFR-2 ligands (4, 44). 
 
Inflammation 
Inflammation is a complex biological process in response of vascular tissues reaction 
to harmful stimuli such as irritants, pathogen infection and tissue injury.  Inflammation is a 
protective attempt by the organism to remove injurious substances as well as initiate the 
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 healing process for the tissue.  Inflammation is a multi-step process involving chemokine 
generation at the infected tissue (45).  Chemokines are a group of small proteins with a 
variety of biological functions including selective recruitment and activation of cells during 
inflammation.  Chemokines migrate into the luminal side of the endothelial cells and bind to 
leukocytes within the blood vessel.  This leukocyte-chemokine interaction triggers leukocyte 
extravasation and migration towards the infected tissue.  The roles of heparin and HS 
involved in regulating inflammatory responses have been noticed recently (46).  It has been 
shown that chemokines are heparin binding proteins (47); the HS and chemokine interactions 
have been determined to be essential for the presence of chemokines on the luminal surface 
of endothelial cells (47).  HS also binds to cell adhesion molecules (such as L- and P-
selectins), as well as, growth factors and growth factor receptors to regulate leukocyte 
migration through the blood vessel wall (48, 49).  Although the mechanism is not fully 
understood, it is generally accepted that the sulfation patterns of HS direct the interactions of 
L-selectin and chemokines (50, 51).  For example, the heparin carrying 6-O-sulfo groups 
exhibit anti-inflammatory effects by blocking the binding of HS and L- and P-selectins (52).  
Therefore, developing HS-based anti-inflammatory agents attracts a lot of interest. 
 
Tumor growth, metastasis and heparanase 
Clinical studies have clearly demonstrated the benefits of treating cancer patients with 
heparin, especially LMW heparin. Tumor cells release procoagulant molecules to activate 
factors X and VII.  The interaction between immune and malignant cells activates platelets, 
factor XII, and factor X, leading to thrombin production and thrombosis. Thus, the 
anticoagulant properties of heparin are useful against thrombosis in cancer (22).   Clinical 
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 studies also indicate that heparin’s antiangiogenic and antimetastatic properties may also 
contribute to its anticancer activity.  For example, studies have found that the administration 
of LMW heparin has improved the survival rate of the patients with small cell lung cancer 
from 29.5% to 51.3%, while another commonly used anticoagulant drug, warfarin, did not 
exhibit the anticancer activity (22, 53 and 54).  However, clinical evidence for heparin use as 
an antimetastatic and antiangiogenesis agent is not conclusive and anticoagulant side effect 
limits the anticancer application of HS (55).   
Heparanase is an endo-β-D glucuronidase that cleaves HS into fragments ranging from 
10 to 20 saccharide units (56-59) (Figure 3).  Heparanase is highly conserved and so far only 
a single form has been found.  Heparanase is involved in several physiological and 
pathological processes, such as wound healing, embryonic development and HS cleavage. 
Heparanase is attributed to cancer by two aspects: firstly, heparanase degrades the HS in the 
extracellular matrix, facilitating cell invasion and metastasis; secondly, by degrading HS, 
heparanase is involved in stimulating angiogenesis through the release of HS-bound growth 
factors such as vascular endothelial growth factor (VEGF) and FGFs.  Therefore, the role of 
heparanase in tumorigenesis makes it an attractive anti-cancer target (60).  Progen 
Pharmaceuticals has developed phosphomannopentose sulfate (PI-88), a mixture of highly 
sulfated monophosphorylated mannose oligosaccharides to inhibit heparanase activity 
(Figure 3).  PI-88 also competes with HS for binding to growth factors such as FGF-1 and 
FGF-2, consequently reducing their ability to stimulate tumor angiogenesis.  Unfortunately, 
although phase II studies of PI-88 in patients with numerous cancers showed promising 
results, Progen Pharmaceuticals recently terminated the phase III trial of PI-88 for several 
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 reasons such as modest results to treat malignancies, lack of a global distributor, and its 
immune-mediated thrombocytopenia (22, 61).   
 
 
 
Fig 3. Substrate specificity and inhibitor for heparanase.  Panel A is the substrate specificity of heparanase.  
Panel B is the Structure of PI-88, the inhibitor of heparanase. 
 
Although the molecular mechanism for the linking cancer and HS is not fully 
understood, it is suspected that the saccharide structures exhibiting anticancer activity are 
different from those carrying anticoagulant activity as determined in a mice model (62). 
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 Because the anticoagulant properties of HS/heparin could limit dosing for its anticancer 
purposes, synthesis of non-anticoagulant HS with antiangiogenic and antimetastatic 
properties attracts considerable interest in exploiting HS or HS-like molecules for the 
development of anticancer drugs. 
 
PF4 and thrombocytopenia 
PF4, a polypeptide with 70 amino acids, belongs to the chemokine family (4).  PF4 is 
released from platelets and is believed to associate with inflammation and wound healing 
which is a result of its ability to neutralize the activity of heparin and HS (4).  However, 
when heparin binds to PF4, it can induce heparin-induced thrombocytopenia (HIT), a serious 
side effect of heparin.  HIT occurs in approximately 3% of patients receiving unfractionated 
heparin and about 0.2% in those patients receiving low molecular weight heparin (63).  HIT 
is an immunologically induced loss of platelets.  In HIT, the immune system forms 
antibodies against heparin when heparin is bound to PF4.  The antibodies form a complex 
with heparin and PF4 in the bloodstream.  The tail of the antibody then binds to the FcγIIa 
receptor, a protein on the surface of the platelet.  This results in platelet activation and the 
formation of platelet microparticles, which initiate the formation of blood clots; the platelet 
count falls as a result of this clotting (64, 65).  It is believed that PF4 recognizes a long 
sulfated domain in HS and the IdoUA2S residue in HS has been identified to be important for 
binding to PF4 (4, 66 and 67).  The optimal size of oligosaccharide needed to form a 
complex with PF4 is about a hexadecasaccharide, although the minimal size for PF4 binding 
is an octasaccharide for heparin (4, 68-70).  Furthermore, the interaction of the heparin 
analogues with PF4 is facilitated by a higher degree of sulfation and a more flexible 
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 conformation on the backbone of heparin (4, 68).  Based on this observation, it is viable to 
design anticoagulant heparin derived oligosaccharides without binding to PF4.  For example, 
Petitou and colleagues have successfully synthesized anticoagulant oligosaccharide without 
binding to PF4 (71).  
 
Section 3. Structure and activity relationship of HS 
AT-binding domain 
Only a fraction of HS binds to AT and exhibits anticoagulant activity. About 1-10% 
of HS binds to AT while about 30% of heparin binds to AT, suggesting that AT recognizes a 
special sequence of HS (3).  Studies have revealed that the anticoagulant drug heparin and 
HS contain a structurally defined AT-binding pentasaccharide sequence with the structure of 
–GlcNS (or Ac) 6S-GlcUA-GlcNS3S6S-IdoUA2S-GlcNS6S- (72-74) (Figure 4).  The AT-
binding site is the essential motif for the anticoagulant activity of heparin and HS.  Binding 
to this pentasaccharide unit will trigger a conformational change of AT and accelerate the 
inhibition of factor Xa.  However, the pentasaccharide unit only inhibits the activity of factor 
Xa. The structural requirements needed for HS binding to AT were proven via chemically 
synthesized pentasaccharides with various combinations of sulfo groups and carboxyl groups. 
The 3-O-sulfation of a glucosamine residue (3-O-sulfation is circled) is the critical 
modification to generate the AT binding site.  Removal of 3-O-sulfo group decreased the 
binding affinity to AT by nearly 20, 000 fold (3).  
A larger oligosaccharide is required to inhibit both anti-Xa and anti-thrombin activity. 
The oligosaccharide consists of an AT-binding domain, a linker region and a thrombin-
 13
 binding domain.  Heparin/HS acts as a template to facilitate the AT-mediated inhibition of 
thrombin.  Petitou et al proved that the order of the three domains is essential for thrombin 
inhibition, namely, the AT-binding domain must be positioned at the reducing end of the 
linker region and the thrombin-binding domain must be located at the nonreducing end of the 
linker region.  The linker region forms a bridge that has no interaction with either of the 
proteins.  Compare to the AT-binding domain, the interaction of thrombin and the thrombin-
binding domain is less specific.  The minimum size to inhibit both factor Xa and thrombin is 
found to be a pentadeca-saccharide (71). 
 
 
 
Fig 4.  The structure of the AT-binding pentasaccharide.  The 3-O-sulfation of the glucosamine residue (3-
O-sulfo group is circled) is the critical modification to generate the AT binding site.  GlcNS(Ac)6S, 
GlcUA, GlcNS3S6S, IdoUA2S and GlcNS6S represent the abbreviation of the individual monosaccharide 
residues. 
 
HSV-1 gD binding domain 
The minimum size of HS that will bind to gD is found to be an octasaccharide (18, 
21). An octasaccharide binding to gD was isolated from a 3OST3-modified octasaccharide 
library with a binding affinity of 18 μM.  Based on mass spectrometry, the isolated 
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 octasaccharide was determined to be ΔUA-GlcNS-IdoUA2S-GlcNAc-GlcUA2S (or 
IdoUA2S)-GlcNS-IdoUA2S-GlcN3S6S (∆UA is deoxy-α-L-threo-hex-enopyranosyluronic 
acid) (Figure 5).   It is very interesting to find that a rare GlcNH2 unit is involved in the 
binding of HSV-1 (gD), and that the binding octasaccharide contains an unique GlcN3S6S 
linked to a IdoUA2S at the non-reducing end (18). 
 
 
 
Fig 5. Chemical structures of gD, FGF-2 and FGF-1 binding sites. 
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 FGF binding domain 
HS had been shown to enhance the formation of FGF-FGFR complexes and stabilize 
FGFR oligomers.  The most well studied FGFs are FGF-1 and FGF-2. Studies revealed that 
the minimal heparin structure binding to FGF-2 is a pentasaccharide of –UA-GlcNS-UA-
GlcNS-IdoUA2S-, while the HS sequence binding to FGF-1 is 5-7 monosaccharide units and 
contains a critical trisulfated disaccharide unit with the sequence IdoUA2S-GlcNS6S.  It is 
interesting to find that 6-O-sulfation is only necessary for FGF-1 binding (4, 22) (Figure 5).  
The studies for HS binding to FGFR indicate that FGFR contains a binding site interacting 
with GlcNS6S.  Based on the crystal structure of FGF, FGFR and the heparin decasaccharide 
and biochemical studies, the active HS fragment must be at least a decasaccharide in order to 
trigger the dimerization of FGFR and initiate downstream cell signaling (4, 41-44). 
 
Section 4. Biosynthesis of HS  
Heparin and HS share the same biosynthetic pathway.  Understanding the 
biosynthetic mechanism of HS provides a tool for altering the synthesis of HS in the cells, 
and helps to delineate the contribution of HS in a specific biological process.  Consequently, 
the results can be employed to improve the pharmacological drug properties of anticoagulant 
heparin and aid in the development of HS/heparin-based therapeutic agents with anticancer 
and antiviral activities. It should be noted that unlike proteins and nucleic acids, the synthesis 
of polysaccharides does not have a template; the specific saccharide sequences are governed 
by the expression level of HS biosynthetic enzymes (8, 13).  The biosynthesis of HS is 
accomplished by a complex pathway involving backbone elongation and multiple 
modification steps (Figure 6).  HS biosynthesis takes place in the lumen of the Golgi 
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 apparatus, although the core protein is synthesized in the endoplasmic reticulum (ER). The 
biosynthesis of HS is initiated as a copolymer of GlcUA and GlcNAc, which is catalyzed by 
copolymerases (EXT1 and EXT2) (7).  The backbone is then modified by a C5-epimerase 
(C5-epi) and different sulfotransferases.  The first modification is N-deacetylation/N-sulfation 
to form GlcNS by N-deacetylase/N-sulfotransferase (NDST).  NDST is a dual function 
enzyme that catalyzes the removal of the acetyl group from a GlcNAc residue and the 
transfer of a sulfo group to form a GlcNS residue.  NDST has four different isoforms (75).  
After the N-sulfated backbone is generated, C5-epi converts the neighboring GlcUA unit on 
the reducing side to an IdoUA unit.  The chain modification proceeds with 2-O-sulfation of 
IdoUA/GlcUA (with a preference to IdoUA), 6-O-sulfation of glucosamine, and 3-O-
sulfation of glucosamine by different O-sulfotransferases (OSTs).  C5-epi and 2-O-
sulfotransferase (2OST) only have one isoform, while 6-O-sulfotransferase (6OST) has three 
(76) and 3-O-sulfotransferase (3OST) has seven isoforms (3, 13). 
 
Chain initiation 
The biosynthesis of HS is initiated by the formation of a tetrasaccharide which links 
to the core protein: GlcUAβ1-3Galβ1-3Galβ1-4Xylβ-O-Ser.  This tetrasaccharide also serves 
as the linkage for the biosynthesis of CS (14) (Figure 7).  The formation of this 
tetrasaccharide linkage unit is catalyzed by the sequential actions of four glycotransferases: 
xylotransferase (XT), galactosyltransferase I (GalTI), galactosyltransferase II (GalTII) and 
glucuronosyltransferase I (GlcUATI).  XT is the first enzyme to intiate the synthesis of the 
linkage tetrasaccharide at a specific serine residue of the core protein (77).  Although the 
mechanism by which XT recognizes the substrate core proteins and selects the Ser residue is 
 17
 still unclear, a Ser-Gly repeating dipeptide seems to be the minimum structural requirement 
for the xylosylation to occur, and a Glu or Asp residue of the core protein is often present in 
the vicinity of the Ser-Gly sequence (78).  Once the xylose is transferred to the core protein, 
two galactosyltransferases, GalTI and GalTII, transfer two galactoses onto xylose to form 
Galβ1-3Galβ1-4Xylβ1-O-Ser (79, 80).  The last enzyme GlcUATI transfers a GlcUA 
molecule to the existing glycan chain to form GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser (14). 
 
Chain polymerization 
The tetrasaccharide linkage to the core protein is the common precursor for the 
biosynthesis of both HS and CS polysaccharide chains.  The critical step that differentiates 
polymerization of HS from that of CS is the addition of a GlcNAcα1-unit instead of the 
GalNAcβ1-unit to the nonreducing end of the tetrasaccharide.  The enzyme HS GlcNAc 
transferase II (GlcNAcTII) adds GlcNAc to the growing HS chain (81).  Once the GlcNAc 
unit is coupled to the linkage tetrasaccharide, polymerization for HS synthesis is committed 
by adding GlcUA and GlcNAc alternatively.  The enzymes encoded by the members of the 
Exostosin genes, EXT1 and EXT2; carry out the polymerization of the HS backbone (Figure 
7).  EXT1 and EXT2 function as a hetero-oligomeric complex, exhibiting both GlcNAC 
transferase and GlcUA transferase activities (82, 83).  The complete loss of both EXT genes 
is embryonic lethal due to the shorter HS chain links to the core protein in EXT knockout 
mice.  Partial loss in either isoform leads to bone exostosis, a genetically heterogeneous 
human disease characterized by bony outgrowths near the ends of the long bones (22, 84 and 
85). 
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Fig 6. HS biosynthetic pathway.  Synthesis is initiated with a copolymer of GlcUA and GlcNAc by HS 
copolymerases (EXT1 and EXT2).  The first modification is to form the N-sulfo glucosamine unit (GlcNS) 
by N-deacetylase/N-sulfotransferase (NDST).  The C5-epimerase then converts the neighboring GlcUA on 
the reducing side to an IdoUA unit. Chain modification proceeds with 2-O-sulfation at iduronic acid (or to 
a lesser extent at a GlcUA), 6-O-sulfation at glucosamine, and 3-O-sulfation at glucosamine by different 
O- sulfotransferases.  The reactions involved in polymer elongation are not shown (13). PAPS is the 
natural sulfo donor. 
 
NDST 
The synthesis of GlcNS by NDST is the very first step of a series of modifications of 
the backbones.  NDST has four different isoforms which determine the N-sulfation pattern of 
the HS backbone.  It is hypothesized that GlcNS’s pattern affects the location of downstream 
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 O-sulfation and epimerization, which consequently dectates the biological function of HS 
(86-88).  Results from cell-based assays demonstrated that the cells that lack of NDST1 or 
NDST4 synthesize low sulfated HS (89).  Targeted gene knockouts of NDSTs also revealed 
the physiological significance of GlcNS in the biosynthesis of HS.  For example, mice 
deficient in NDST1 displayed dramatically reduced amounts of sulfated HS, and died shortly 
after birth (90).  Studies of the conditional knockout of the NDST1 gene revealed that GlcNS 
is essential for synthesizing the HS that regulates L-selectin- and chemokine-mediated 
neutrophil trafficking (91).  NDST2 null mice are viable but lack heparin synthesis in mast 
cells (92).  NDST3 null mice are fertile and exhibit only minor hematological and behavioral 
phenotypes (93).  The distinct phenotypes of different NDST knockout mice strongly suggest 
that unique GlcNS distribution directs the synthesis of HS with specific physiological 
functions. 
 
 
 
Fig 7. The HS chain initiation and elongation. 
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 C5-epimerase 
The first modification of GlcUA residue is catalyzed by HS C5-epi, which converts 
the configuration of the proton at the C5 position, thus, generating an IdoUA unit (94) (Figure 
8).  Another possible mechanism is the generation of an enol-intermediate rather than a 
carbanion intermediate; however, there is no literature report to support this notion.  C5-epi 
has only one isoform in almost all species examined (14).  A GlcNS unit is required at the 
non-reducing end of the GlcUA for the action of C5-epi, suggesting the C5-epimerization 
rigorously follows N-sulfation.  IdoUA has been suggested to give HS a more flexible 
structure.  In addition, IdoUA is a much more favorable substrate for HS 2OST (95-97), and 
the resultant IdoUA2S plays an essential tole for HS biological functions.  HS isolated from 
C5-epi null mice lacked IdoUA and the predominant sulfated disaccharide is GlcUA-
GlcNS6S.  The lack of C5-epi is also lethal to mice due to an immature lung phenotype, 
abundant skeletal abnormalities, and kidney agenesis (98).   
 
 
 
Fig 8. Proposed mechanism of C5-epimerase. 
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 2OST 
2OST transfers a sulfo group to the 2-OH position of IdoUA or GlcUA (with a 
preference to IdoUA) within HS and 2-O-sulfation is the only sulfation that occurs on the 
uronic acid units.  Just as C5-epi has only one isoform, so does 2OST in most species which 
forms a complex with C5-epi in vivo (99).  The sequence of 2OST is highly conserved across 
species.  Human 2OST shares 97% sequence identity with mouse and 92% identity with 
chicken (100).  It is interesting to note that the phenotypes displayed by 2OST knockout mice 
are similar to those observed in C5-epi null mice.  However, in contrast to C5-epi null mice, 
the loss of 2-O-sulfation in mutants is compensated by a 13% increase in 6S and a 9% 
increase in NS (101, 102).  Moreover, unlike C5-epi-null mice, 2OST knockout mice survive 
until birth, but die soon after due to kidney agenesis (103).  Similar to C5-epi, GlcNS at the 
non-reducing end of the acceptor residue significantly enhances the susceptibility of IdoUA 
or GlcUA to 2OST modification.  
 
6OST 
HS 6OST catalyzes the transfer of a sulfo group to the C6 position of glucosamine 
residue (GlcN) to form 6-O-sulfo glucosamine.  6-O-sulfation occurs predominantly at the 
GlcNS residue, generating a GlcNS6S moiety.  However, in some cases, it can also occur at 
the GlcNAc residue, generating a GlcNAc6S moiety; 6-O-sulfation is the only type of 
sulfation that occurs at the GlcNAc residue (104).  Three isoforms of 6OST have been 
identified with approximately 50% similarity (104).  The 6-O-sulfation by 6OST1 
predominantly occurs at the GlcNS residues, while other 6OST isoforms can modifiy 
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 GlcNAc to yield GlcNAc6S.  Furthermore, 6OST1 prefers the IdoUA-GlcNS over GlcUA-
GlcNS while 6OST2 favors GlcUA-GlcNS more than IdoUA-GlcNS. 6OST3 has almost 
equal activities towards both disaccharide structures (105) (Figure 9).  6OST1 null mice had 
growth retardation, aberrant eye and lung morphogenesis, and impaired placenta function and 
died at or soon after birth (106).  More studies are necessary to dissect the individual roles of 
6OST isoforms as well as substrate specificity. 
 
 
 
Fig 9. Substrate specificity of 6OSTs. The 6-O-sulfation is circled. 
 
3OST 
3OST represents the most extended gene family among all HS sulfotransferases.  HS 
3OST is present in seven isoforms, including 3OST1, 2, 3A, 3B, 4, 5 and 6.  Since 3OST3A 
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 and 3OST3B have almost identical amino acid sequence in the sulfotransferase domain, 
3OST3 represents both enzymes (3).  3OSTs transfer a sulfo group to the 3-OH position of a 
GlcN residue.  Each isoform of 3OST transfers the sulfo group to the GlcN residue that is 
linked at the non-reducing end.  This modification falls into three types: First, 3OST1 
transfers a sulfo group to the glucosamine unit that is adjacent to an unsulfated glucuronic 
acid.  Second, 3OST3 transfers a sulfo group to the glucosamine unit that is adjacent to a 2-
O-sulfated iduronic acid.  Third, 3OST5 has both 3OST1 and 3OST3-like activity.  In other 
word, 3OST5 can transfer a sulfo group to the glucosamine unit that is adjacent to GlcUA, 
IdoUA and IdoUA2S (3) (Figure 10).  As mentioned previously, 3OST1-modified HS binds 
to AT and regulates the blood coagulation cascade.  3OST3 modified HS is bound by HSV-1 
gD, serving as an entry receptor for the virus.  HS modified by 3OST5 endows both 
anticoagulant activity and the ability to promote HSV-1 entry (107-110).  Among seven 
isoforms of 3OST, only 3OST1 has been knocked out in mice; however, 3OST1 null mice do 
not exhibit any procoagulant phenotype (111).  These results can be explained by the fact that 
other isoforms of 3OST, such as 3OST5, may take place of 3OST1 to synthesize a low level 
of anticoagulant HS. 
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Fig 10. Substrate specificity of 3OSTs.  The 3-O-sulfation is circled. 
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 Substrate recognition of 2OST and 3OSTs 
Understanding the substrate recognition mechanism is essential to advance the 
enzymatic synthesis and elucidate the biosynthetic mechanism of HS.  Recently, our lab, in 
collaboration with Dr. Lars Pedersen, solved the crystal structure of chicken 2OST (D69–
N356) at the resolution of 2.65 Å, in complex with 3′-phosphoadenosine 5′-phosphate (PAP).  
The crystal structure of 2OST has distinct differences from other existing HS 
sulfotransferases structures, although their global structure is similar (100).  The most distinct 
structural difference between 2OST and the other HS sulfotransferases is that 2OST appears 
to function as a trimer.  Mutational analysis helped identify amino acid residues that are 
responsible for substrate specificity.  Our lab found that the mutant R189A only transferred 
sulfates to GlcUA moieties within the polysaccharide while mutants Y94A and H106A 
preferentially transferred sulfates to IdoUA units.  Our results demonstrate the feasibility for 
modifying the substrate specificity of 2OST to synthesize HS with a specified sulfation 
pattern carrying unique biological functions (100). 
Similar to 2OST, our lab used crystal structures to guide our mechanism of action 
study for 3OSTs.  Our lab, in collaboration with Dr. Lars Pedersen, solved the crystal 
structure of 3OST1 and 3OST5 with PAP at the resolution of 2.5 Å and 2.3 Å, respectively. 
A ternary complex of 3OST3/PAP/tetrasaccharide substrate was also solved at the resolution 
of 1.9 Å (108-110).  The overall structures of 3OST1, 3 and 5 are very similar.  Based on 
crystal structures, sulfotransferases were engineered to create more homogenous or novel HS.  
However, our initial efforts at the mutating the catalytic site failed; these mutants have no 
catalytic activities, suggesting that these residues are essential for catalytic function.  By 
comparing the substrate binding clefts of 3OSTs, it is noted that two residues (Glu88 and 
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 His271) in 3OST1 appear to form a ‘gate’ across the end of the substrate binding cleft, which 
is 6.7 Å in distance.  In contrast, in 3OST3 and 3OST5, the distance of the corresponding 
‘gate’ is 14.2 Å.  Narrowing the gate by mutating S120 and A306 of 3OST5 to S120 E, 
A306H enhanced the AT-binding activity of the HS product, transforming 3OST5 toward 
3OST-1like enzyme.  Similarly, opening the gate by mutating E88 and H271 of 3OST1 to 
E88G, H271G reduced the AT-binding activity of the HS product, thus demonstrating 
3OST5-like activity (110). 
Our results have given insight into the mechanism used by 3OST isoforms, especially 
for 3OST5 and 3OST1, to determine substrate specificity.  It appears that the enzyme 
employs two sites, namely the catalytic site and the gate, to select the appropriate 
polysaccharide substrate.  The catalytic sites are highly homologous among isoforms, and the 
amino acid residues involved in binding to the substrate are essential for 3-O-sulfotransferase 
activity.  The gate residues appear to distinguish the IdoUA2S unit near the catalytic 
sulfation site.  Alterations of the gate residues could allow the isoform to change substrate 
selectivity (22, 110).  Similar to 2OST, our results demonstrate the feasibility of modifying 
the substrate specificity of sulfotransferases to synthesize HS with a specified sulfation 
pattern carrying unique biological functions. 
 
Section 5. Biosynthesis of heparosan 
Not only mammalians produce HS and HS-like structures. Some bacteria also form 
surface polysaccharide capsules that are structurally identical or similar to HS 
polysaccharides although these polysaccharides lack sulfation and iduronic acid unit (112-
115).  For example, certain pathogenic strains of E. coli (112, 113) and P. multocida (114, 
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 115) make capsules composed of polymers similar to a unepimerized and unsulfated HS 
backbone, known as heparosan.  Heparosan protects the bacteria from attack by host defenses, 
giving the bacteria advantages for establishing infections. 
 
Heparosan synthases from E.coli 
Two enzymes, KfiA and KfiC, are believed to be responsible for the synthesis of 
heparosan in the E. coli K5 strain.  KfiA was originally identified by Roberts’ group to 
encode GlcNAc transferase activity, although the purified protein was not obtained (112). 
Our lab developed an effective approach to express KfiA based on the published sequence 
(113).  The recombinant KfiA was harvested from bacterial culture at the yield of 10 mg/L.  
The substrate characterization study concluded that KfiA has high specificity for the UDP-
GlcNAc substrate.  Also, KfiA can efficiently transfer a GlcNAc group to an acceptor of 
various sizes, including disaccharides.  KfiC of E. coli K5 has been reported to carry 
glucuronyl transferase activity.  Although we obtained an active form of KfiC by 
coexpressing with KfiA, the level of expression is insufficient for the use in the synthesis of 
HS oligosaccharide backbones (13). 
 
Heparosan synthases from P. multocida 
Additional heparosan biosynthetic enzymes were isolated from P. multocida. 
DeAngelis’ group successfully identified and cloned heparosan synthase pmHS1 (114) and 
pmHS2 (115) from P. multocida.  Unlike KfiA, pmHS1 and pmHS2 have both GlcNAc and 
GlcUA transferase activities although the substrate specificities of pmHS1 and pm HS2 are 
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 believed to be distinct.  The results from these studies could provide a new approach for the 
synthesis of heparin/HS backbone (13). 
 
Section 6. Chemical and enzymatic synthesis of HS 
Chemical synthesis of AT-binding oligosaccharides 
Chemical synthesis is a powerful approach to obtain structurally defined heparin/HS 
oligosaccharides.  The most successful example is the total synthesis of an AT-binding 
pentasaccharide.  This drug is marketed with the trade name Arixtra used for preventing 
venous thromboembolic incidents during surgery (Figure 11).  However, Arixtra only 
inhibits factor Xa activity and the synthesis of Arixtra requires 60 steps with only a 0.5% 
yield (72-74).  Although the approval of Arixtra by FDA represents the climax in the 
chemical synthesis of HS oligosaccharides, the high cost of Arixtra limits its application.  In 
the search for antithrombotic saccharides with reduced synthetic complexity and better 
pharmacological properties, a simplified pentasaccharide analogue, in which the hydroxyl 
groups are methylated and the N-sulfated groups are replaced by O-sulfates, was synthesized 
(Figure 11).  This analogue of Arixtra, called Idraparinux, only takes about 25 synthetic 
routes prepared from glucose.  Idraparinux interacts more strongly with AT than Arixtra (Kd 
of 1 nM compare to 50 nM of Arixtra).  Idraparinux also exhibits longer duration of action; 
t1/2 in human is 120 h, compared to 17 h of Arixtra, thus enabling once-weekly administration 
(116).  However, clinical trials for Idraparinux have been halted after a number of 
participants developed excessive bleeding (117).  In order to improve its pharmacological 
efficacy, a heparin mimetic (SR123781) with 16 saccharide units has been synthesized with 
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 both anti-Xa and anti-thrombin activities (Figure 11).  The advantage of this compound is 
that it is not only capable of inhibiting newly formed thrombin, but it will also block the 
activity of clot-bound thrombin (116).  However, this compound is a simplified hybrid 
molecule of HS oligosaccharides and highly sulfated glucose units that are not natural 
occurring heparan sulfate/heparin structures (71, 72). The compound is effective in baboon 
(118); however, it has not been marketed.  
 
 
 
Fig 11. The chemical structures of Arixtra, Idraparinux and SR123781. 
 
Chemical synthesis of peptide/HS oligosaccharide conjugate mCD4-HS12 
Recently, researchers have made a synthetic CD4-heparan sulfate conjugate that acts 
as a novel type of fusion inhibitor for HIV-1 (119) (Figure 12).  This inhibitor—mCD4-
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 HS12—contains a CD4-mimetic peptide linked to a HS dodecasaccharide.  The CD4-mimetic 
peptide binds to the HIV-1 envelope glycoprotein gp120, which drives the exposure of the 
coreceptor binding domain and renders it to be blocked by the HS part of the inhibitor.  Thus, 
mCD4-HS12 targets two conserved regions of gp120 that are crucial for cell entry by HIV-1. 
The inhibitor has strong antiviral activity toward CCR5-tropic, CXCR4-tropic and dual-
tropic HIV-1 strains.  The synthesis was divided into two parts: the CD4 mimetic peptide 
(mCD4g) engineering and chemical synthesis of the HS dodecasaccharide moiety.  The 
mCD4g is a 27 amino acid CD4 mimetic which has three mutations compared to the initial 
mCD4: F5K mutation, which allows proper HS attachment and two mutations K11S and 
K18R to avoid the unnecessary HS attachment points.  The author also introduced a 
maleimido group on the side chain of lysine 5, leading to a mCD4-PEO2-Mal peptide that 
will conjugate with the HS moiety.  The HS docasaccharide was synthesized using a highly 
convergent method by utilizing a well established chemistry technique.  The authors could 
synthesize up to 20 mg of dodecasaccharide HS12 although only 710 μg mCD4-HS12 was 
reported (119). 
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Fig 12. The chemical structures of HS12, CD4-HS12 and mCD4g. 
 
Enzymatic synthesis of biological active polysaccharides 
Although many efforts continue to pursue the synthesis of HS oligosaccharides, it has 
been difficult to generate authentic HS structures larger than a hexasaccharide solely utilizing 
chemical synthesis.  HS biosynthetic enzymes offer a promising alternative approach for the 
synthesis of large heparin/HS oligosaccharides with the desired biological activities.  Several 
groups have reported their attempts to synthesize HS using biosynthetic enzymes to produce 
a polysaccharide product with biological activity (13, 120-124).  For example, Lindahl and 
colleagues have reported a chemoenzymatic approach for the synthesis of an anticoagulant 
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 heparin mimic from heparosan (120).  The heparosan was initially N-deacetylated/N-sulfated 
and then GlcUA units were converted to the IdoUA unit by the C5-epi.  After further 
chemical persulfation by pyridine sulfate and followed by selective desulfation, a heparin 
mimic, known as neoparin, was generated.  Although neoparin has levels of anti-Xa and anti-
thrombin activity similar to those of heparin, unwanted products, such as 3-O-sulfo 
GlcUA/IdoUA, were present in the polysaccharide, suggesting the limitation in the 
selectivity of chemical sulfation/desulfation in HS synthesis. 
Our lab has significantly improved the enzyme-based synthesis of HS in several 
aspects.  First, we enhanced the expression of enzymes and successfully coupled the 
synthesis with a 3’-phosphoadenosine-5’-phosphosulfate (PAPS) regeneration system, 
allowing us to prepare HS in milligrams quantities (123).  Second, we utilized this approach 
to identify a new anticoagulant HS, named Recomparin, which has a simplified structure.  
PAPS is a sulfo donor for sulfotransferases, which is prohibitively expensive for large 
scale enzyme-based synthesis.  The PAPS regeneration system, initially developed by 
Wong’s lab (125), has been applied in HS/heparin enzymatic synthesis (123).  PAP is formed 
when the sulfo group is transferred to an acceptor.  However, PAP inhibits the HS 
sulfotransferases activity, making milligram-scale synthesis difficult without continuously 
removing PAP.  The PAPS regeneration system converts PAP to PAPS through the action of 
arylsulfotransferase-IV (AST-IV), which catalyzes the transfer of a sulfo group from p-
nitrophenyl sulfate (PNPS) to PAP. Thus, HS sulfotransferases use PNPS, instead of PAPS, 
as the sulfo donor (Figure 13).  The PAPS regeneration system offers two advantages for 
large–scale synthesis.   First, it converts PAP to PAPS, eliminating the PAP inhibition effect.  
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 Second, the cost for PNPS is about 1000 times lower than that for PAPS; therefore, its use 
significantly reduces the cost of sulfotransferase-catalyzed reactions (13). 
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Fig 13. PAPS regeneration system.  The PAPS regeneration system converts PAP to PAPS through the 
action of recombinant arylsulfotransferase-IV, which catalyzes the transfer of sulfo group from p-
nitrophenyl sulfate (PNPS) to PAP.  Thus, HS sulfotransferases use PNPS, instead of PAPS, as the sulfo 
donor (13). 
 
Our lab, in collaboration with the Linhardt group, has developed an enzymatic 
approach to the synthesis of bioactive HS polysaccharides from HS backbones, starting from 
the chemically desulfated N-sulfated (CDSNS) heparin (123).  Only three enzymatic steps 
are required to synthesize anticoagulant HS (HS1 in Figure 14) in milligrams.  Immobilized 
enzymes were employed to permit reuse and to improve the stability of HS sulfotransferases. 
We further tested the activity of HS1 in inhibiting factor Xa and IIa.  As expected, HS1 is a 
potent inhibitor of factor Xa and IIa via AT-mediated process. Its inhibition activity is very 
similar to heparin, suggesting that our enzyme-based modification system is indeed capable 
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 of converting HS backbones to anticoagulant polysaccharides.  We also measured the 
binding affinity of AT to HS1 by surface plasmon resonance (SPR), which showed that the 
anti-IIa and anti-Xa activities of HS1 correlated to its binding affinity to AT.  We also 
generated other types of HS polysaccharides which bind to FGF-2 or HSV-1 gD.  Taken 
together, this demonstrates the feasibility of large-scale chemoenzymatic synthesis of 
heparin/HS with desired biological activities and could be used as a unique tool to explore 
the biosynthesis of heparin/HS (13).   
 
 
 
Fig 14. Enzymatic synthesis of anticoagulant CDSNS heparin.  The synthesis began with chemical de-
sulfated/N-sulfated (CDSNS) heparin.  CDSNS heparin was modified by 2OST, 6OST and 3OST1 to 
generate anticoagulant polysaccharide HS1 (13). 
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 Our lab then applied this approach to the synthesis of a small HS library with 
different sulfation patterns (124).  In this study, N-sulfo heparosan had been 
chemoenzymatically prepared from heparosan.  A combination of recombinant HS 
biosynthetic enzymes was used to modify N-sulfo heparosan.  Our lab discovered one 
polysaccharide, known as Recomparin (Figure 15).  Recomparin showed strong AT-mediated 
anticoagulant activity.  Disaccharide analysis suggested that Recomparin consists of a 
repeating tetrasaccharide (–GlcUA-GlcNS3S±6S-GlcUA-GlcNS6S-).  It was somewhat 
surprising to discover that Recomparin has strong anticoagulant activity despite the fact that 
Recomparin contains no IdoUA2S unit.  Previous studies showed that the IdoUA2S unit was 
critical for a pentasaccharide to bind to AT (72).  Furthermore, IdoUA adopts a skew boat 
(2S0) or chair (1C4) conformation, while GlcUA is mainly found in the chair conformation 
(4C1) (Figure 1) (2).  The 2S0 conformation was generally believed to be necessary for 
binding to AT (126).  Our results indicated that the structural flexibility of the IdoUA unit is 
less important in the polysaccharide-AT interaction.  Indeed, further experimental data 
suggests that the IdoUA unit is essential for binding to AT if the oligosaccharide is smaller 
than a hexasaccharide, while the IdoUA unit is not essential when the oligosaccharide is 
larger than an octasaccharide (124).  Since IdoUA2S units are responsible for heparin 
binding to PF4 (20) and FGF (19), our results can help design novel heparin-based 
anticoagulant drugs with reduced chances of inducing HIT or stimulating cell growth.  
Indeed, we found that Recomparin, unlike heparin, had no activity in stimulating FGF/FGFR 
mediated cell proliferation, demonstrating that the anticoagulant activity and the activity in 
stimulating cell proliferation can be separated at the polysaccharide levels (13). 
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Fig 15. Enzyamtic synthesis of Recomparin.  The synthesis began with heparosan. The acetyl group was 
removed by sodium hydroxide to yield the GlcNH2 unit.  The resultant GlcNH2 unit was then N-sulfated 
by NST and it was further modified by 6OST and 3OST1 to generate Recomparin (13). 
 
Enzymatic synthesis of biologically active oligosaccharides 
The next goal is to synthesize the oligosaccharide with precise structures.  Unlike 
oligosaccharide, polysaccharide is difficult to get a structurally define compound and it is 
also difficult to analyze the structure of a polysaccharide.  Therefore, without the fully 
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 characterized oligosaccharide products, it is very hard to evaluate the consistency and 
accuaracy of the enzyme-based methods. 
Rosenberg and colleagues achieved notable progress in the enzymatic synthesis of 
anticoagulant HS/heparin oligosaccharide.  For example, they developed an enzymatic route 
to synthesize a specific HS pentasaccharide that binds to AT (127) (Figure 16).  The authors 
used heparosan as a starting material.  Heparosan was treated with NDST2 to prepare a 
partially N-sulfated polysaccharide, which was partially cleaved by heparin lyase I to 
generate a mixture of oligosaccharides of different sizes.  A hexasaccharide fragment was 
separated by high-performance liquid chromatography (HPLC).  This hexasaccharide was 
further treated with C5-epi and 2OST1 to generate an IdoUA2S residue at the reducing end.  
Next, selective 6-O-sulfation of two glucosamine units located at middle and non-reducing 
end was achieved by a 6OST1 and 6OST2a mixture.  After removal of the terminal uronic 
acid residue at non-reducing end by Δ4, 5 glycuronidase, 3-O-sulfation of the middle 
glucosamine residue in the resulting pentasaccharide was accomplished by 3OST1, 
generating the AT-binding pentasaccharide.  Either PAP34S or PAP35S was used in the 
3OST1 modification step for structural characterization by electrospray ionization mass 
spectrometry (ESI-MS) or a gel mobility assay, respectively.  Gel mobility assays confirmed 
that the synthetic pentasaccharide effectively binds to AT.  This approach accomplished the 
synthesis of heparin pentasaccharide with fewer steps and a two-fold higher product yield as 
compared to traditional chemical synthesis.  This demonstrated for the first time the 
feasibility of enzymatic synthetic strategies to synthesize structurally defined HS. However, 
only microgram amounts of product were generated, precluding further biological function 
studies (13). 
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Fig 16. Enzymatic synthesis of AT-binding pentasaccharide.  Heparosan was used as starting material. Six 
enzymatic steps were utilized to synthesize an AT binding pentasaccharide with anticoagulant activity. 
Either PAP34S or PAP35S was used in 3OST1 modification step (circled) for structural characterization by 
ESI-MS or gel mobility assay respectively. 
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 Our lab also utilized the enzyme-based approach to prepare a structurally defined 
octasaccharide with the purpose of developing novel anti-herpes drugs by targeting the viral 
entry step (13, 128).  The synthesis of 3-O-sulfated octasaccharide was completed by 
incubating purified 3OST3 enzyme and an octasaccharide substrate (13) (Figure 17).  The 
octasaccharide substrate was purified from partially depolymerized heparin with heparin 
lyases.  This 3-O-sulfated octasaccharide possesses a binding constant (Kd) of 19 μM as 
determined by affinity co-electrophoresis (29), which is comparable to the gD-binding 3-O-
sulfated octasaccharide previously isolated from HS (26).  Further cell based assays (129, 
130) demonstrated that this 3-O-sulfated octasaccharide was indeed an inhibitor for HSV-1 
infection.  The structure of the octasaccharide was characterized by ESI-MS and non-
reducing and reducing end sequence analysis.  The structure has been determined to be 
∆UA2S-GlcNS6S-IdoUA2S-GlcNS6S-IdoUA2S-GlcNS6S3S-IdoUA2S-GlcNS6S.   These 
results demonstrate the application of enzymatic synthesis for a structurally defined HS 
oligosaccharide to inhibit HSV-1 infection (13). 
 
 
Fig 17. Preparation of 3-O-sulfated octasaccharide inhibiting the entry of HSV-1. 3-O-sulfation is circled. 
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 Unnatural UDP donors 
UDP-N-acetylglucosamine (UDP-GlcNAc) and UDP-glucuronic acid (UDP-GlcUA) 
are widely used in the synthesis of heparin/HS oligosaccharides.  The alternative UDP sugar 
donors can help us in the synthesis of unnatural products with novel biological or chemical 
properties.  Several unnatural UDP-sugars have been synthesized and tested as substrates for 
GlcNAc or GlcUA transferase.  For example, DeAngelis and colleagues reported the 
enzyme-catalyzed incorporation of unnatural UDP-sugar derivatives by pmHS1 and pmHS2 
(131).  They found that pmHS1 required highly restricted donor structures, while pmHS2 
was able to utilize several unnatural UDP-sugar analogs.  For example, pmHS2 can accept 
UDP sugars with acetamido-containing uronic acid as GlcUA donors and it can tolerate 
glucosamine derivatives with longer acyl chain as GlcNAc donors.  This flexible specificity 
of pmHS2 could be used to prepare heparin/HS analogs with novel structures.  Recently, in 
order to study the specificity of different GlcUA transferases, Linhardt and colleagues 
synthesized two UDP-GlcUA analogs: uridine 5′-diphosphoiduronic acid (UDP-IdoUA) and 
uridine 5′-diphosphohexenuronic acid (UDP-HexUA) (132).  In this study, pmHS1 and 
pmHS2 were utilized as GlcUA transferases.  Unfortunately, their results demonstrated that 
UDP-HexUA failed to serve as a substrate for pmHS1 and pmHS2.  When UDP-IdoUA was 
used as the substrate, sugar residues were transferred with low activity and only GlcUA was 
incorporated into the products formed.  According to the authors, this is either due to the 
contamination of a small amount of UDP-GlcUA during the chemical synthesis of UDP-
IdoUA, or UDP-IdoUA might be isomerized to UDP-GlcUA by the GlcUA transferases via 
an unknown mechanism.  These studies demonstrated the potential application of unnatural 
UDP-sugars in the chemoenzymatic preparation of synthetic HS/heparin (13).  
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 Section 7. Structural characterization of HS 
Due to the chemical structure of HS, the methods to analyze the structure of HS are 
limited.  In the recent years, several techniques have been employed to analyze the HS 
structures, including disaccharide analysis, mass spectrometry (MS) and nuclear magnetic 
resonance (NMR).   
 
Disaccharide analysis  
Because it is not possible to analyze the structure of full length HS, disaccharide 
analysis is typically used to profile the structures of HS from various sources.  The 
disaccharide analysis, analogy to the amino acid compositional analysis of protein, provides 
the relative ratio of disaccharide building blocks.  Degradation of HS can be achieved by 
either enzymatic or chemical methods.  The enzymes, heparin lyases, are commonly used to 
digest heparin or HS and are naturally produced by the soil bacterium Flavobacterium 
heparinum (133).  This bacterium is capable of utilizing either heparin or HS as its sole 
carbon and nitrogen source.  Heparin lyases cleave heparin/HS by a β-elimination 
mechanism (134) (Figure 18A).  The action generates an unsaturated double bond between 
C4 and C5 of the uronate residue (referred as ∆UA).  The double bond is a sensitive UV 
chromaphore, with the maxium absorption at 232 nm, providing a convenient method for 
detecting the HS fragments produced by enzyme digestion.  The identities of the resultant 
disaccharides can be quantitatively determined by high performance liquid chromatography 
(HPLC, 135) or capillary electrophoresis (CE, 136).  The bacterium produces three lyases, 
heparinases I, II and III, and each has distinct substrate specificities (137, 138).  It is known 
that heparin lyase I cleaves the glycosidic linkage between IdoUA2S and GlcNS where a 
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 highly sulfated domain resides.  Heparin lyase III cleaves 1, 4 linked polysaccharide 
containing GlcNS/Ac (±6S)-GlcUA/IdoUA (with a preference for GlcUA).  Heparin lyase II 
has more flexibility and cleaves the glycosidic linkage at the site either heparin lyase I or III 
recognize (Figure 18B).  Since heparin lyases cleavage results in an unsaturated uronic acid, 
the result from disaccharide analysis of heparin lyase degraded HS can not differentiate 
between GlcUA and IdoUA. 
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Fig 18. Heparin lyases degradation reaction.  Panel A is the proposed elimination mechanism.  Panel B is 
the substrate specificity of heparin lyase I, II and III. 
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 Nitrous acid degradation is a traditional chemical method to degrade the HS (139), 
including low pH (pH 1.5) and high pH degradation (pH 4.5).  Under both conditions, nitrous 
acid leads to deaminative cleavage of the chain (Figure 19).  Unlike heparin lyase cleavage, 
the nitrous acid degradation remains the GlcUA/IdoUA unit, regardless of O-sulfation carried 
by either monosaccharide unit; therefore, it allows the differentiation of GlcUA/IdoUA.  At 
high pH, the nitrous acid only reacts with GlcN; while at low pH, the nitrous acid can cleaves 
HS from GlcNS, therefore, low pH nitrous acid degradation is an effective method to 
differentiate GlcNS and GlcNAc.  Nitrous acid degradation will generate anhydromannose.  
 
 
 
Fig 19. High and low pH degradation of HS. 
 
Mass spectrometry 
Mass spectrometry (MS) requires as low as microgram scale of samples, making it a 
powerful tool to analyze the structure of HS, especially HS oligosaccharides (140-144). 
Depending on the method for preparing the samples, HS oligosaccharides sometimes have no 
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 UV chromophore.  Consequently, it increases the difficulty in identifying and purifying those 
oligosaccharides by HPLC, which is commonly equipped with an on-line UV detector. 
Therefore, MS, especially LC-MS, is highly useful to determine the structure of HS 
oligosaccharides.  In HS analysis, electrospray mass spectrometry (ESI) is widely used and 
typically more sensitive than matrix-assisted laser desorption/ionization (MALDI).  Our lab 
developed a nano ESI-MS method that could detect HS pentasaccharide at a concentration as 
low as 50 nM (140).  MS/MS is rapid and efficient in determining the detailed structures of 
HS oligomers.   For example, Leary and the colleagues developed a heparin oligosaccharide 
sequencing tool (HOST) to analyze HS/heparin oligosaccharides by enzymatic digestion 
combined with ESI-MS/MS (142).  They were able to sequence HS tetra-and hexa-
saccharides by using this tool.  The Linhardt group also developed a MS/MS method to 
distinguish hyaluronic acid and N-acetylheparosan (143); furthermore, they could distinguish 
GlcUA from IdoUA in tetrasaccharide by using electron detachment dissociation (144). 
 
NMR analysis  
NMR analysis can be applied to definitively establish the structure and conformation 
of HS oligosaccharides, especially in solution (145).  For example, nuclear overhauser effects 
(NOEs) have been used to characterize the conformation of IdoUA between 1C4 and 2S0 
conformers and the NMR data has indicated that the 2-O-sulfo group in the IdoA2S residue 
is not directly involved in binding to AT (146).  Moreover, NMR studies of heparin 
tetrasaccharides in the presence of FGF-1 and FGF-2 indicated that FGF binding stabilizes 
the 1C4 conformation of the IdoUA2S residue directly involved in binding.  These studies 
also confirmed a tetrasaccharide is the minimal size binding to FGF-1 and FGF-2 (147, 148). 
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 More recently, the Linhardt group employed NMR spectroscopy to analyze the chemical 
composition and solution structure of stable isotope-enriched heparin (149), which is 
chemoenzymatically synthesized from a uniformly labeled [13C, 15N] N-acetylheparosan.  It 
was found that isotopic enrichment could provide well-resolved 13C spectra with the high 
sensitivity required for conformational studies of heparin as well as its [13C, 15N] N-
acetylheparosan precursor.  The structure of the stable isotope-labeled heparin was 
indistinguishable from heparin derived from animal tissues and provides a novel tool to study 
the interaction of heparin with proteins (149).  The major drawback of NMR analysis is that 
the methods typically require milligram scale of highly purified HS oligosaccharides, which 
has been proved to be very difficult to obtain. 
 
Section 8. Statement of problems 
Heparin is a commonly used anticoagulant drug with annual sales close to $4 billion 
worldwide.  Drawbacks of the drug include the vulnerable supply of raw materials, severe 
side effects, and potential risk of contaminants (13, 150).  Over the past decade, many groups 
have achieved considerable progress in understanding heparin/HS synthesis and biosynthesis, 
especially in the efforts to synthesize structurally defined HS oligosaccharides.  Chemical 
synthesis has been the major route to obtain structurally defined HS/heparin oligosaccharides. 
The most successful example is the total synthesis of the AT-binding pentasaccharide, 
Arixtra, used clinically to prevent venous thromboembolic incidents during surgery. 
Unfortunately, total synthesis is costly and the chemical synthesis of those larger 
oligosaccharides is extremely difficult if not impossible based on currently available methods. 
The synthesis of structurally diversified heparin/HS oligosaccharide still remains a daunting 
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 task.  Enzymatic synthesis will provide an alternative approach to prepare structurally 
defined oligosaccharides (13). 
Enzymatic approaches have successfully synthesized HS from heparosan, producing 
polysaccharide and oligosaccharide end products with high specificity for the biological 
targets (13, 150).  Thus, synthetic heparin will eliminate the possibility of contamination and 
give the drug manufacturer complete control over the safety and purity of the product. 
Optimizing the synthetic procedure will allow us to produce heparin with maximum 
pharmacological effects (13, 150).  
Enzymatic synthesis of polysaccharide results in a mixture, and thus, it is unlikely to 
assess the consistency and structural accuracy of the products. One method is to use heparin 
lyases to digest heparosan.  Indeed, Rosenberg’s lab has used this method to synthesize an 
AT-binding pentasaccharide.  However, controlling the extent of digestion is difficult and HS 
oligosaccharides of other sizes and structures are difficult to achieve in large quantities.  In 
contrast, de novo synthesis using HS backbone synthases provides a promising alternative 
approach.  Bacterial glycosyl transferases offer the hope for the synthesis of HS 
oligosaccharide backbone.  It is known that some bacteria such as E. coli K5 strain and P. 
multocida can produce heparosan.  Therefore, one can take advantage of the synthases 
involved in the biosynthesis of heparosan for HS backbone synthesis (13).  
Our central hypothesis is that the structure of HS is controlled by regulating the 
distribution of GlcNS.  Thus, in this dissertation, we report the development of a unique 
chemoenzymatic approach to synthesize an octasaccharide library with defined positions of 
GlcNS.  Next, a library of oliogosaccharides with defined positions of 6-O-sulfation has also 
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been developed.  Finally, multiple HS biosynthetic enzymes are used to synthesize a heparin-
like anticoagulant dodecasaccharide with homogeneous structure.   
The continuation of this dissertation will improve our understanding of HS 
biosynthesis.  Most importantly, the results will not only allow us to investigate novel 
synthesis of anticoagulant drugs but also lead to a general method for preparation of 
structurally more defined HS structures with various other biological functions and help 
develop novel heparin/HS based therapeutic agents. 
Chapter II MATERIALS AND METHODS 
 
Section 1. Preparation of substrate acceptors and UDP-donors 
Preparation of heparosan from E. coli K5 
E. coli K5 strain was used to produce heparosan, a bacterial polysaccharide with a 
repeating disaccharide N-acetylated glucosamine and glucuronic acid residues.  Heparosan is 
structurally similar to unepimerized and unsulfated HS backbone.  In this study, heparosan 
can be used to mimic HS backbone and can be modified by HS biosynthetic enzymes. 
Heparosan is harvested from E. coli cells in large quantities. Six liters of an overnight culture 
of E. coli K5 was prepared and spun to recover the supernatant; the supernatant was adjusted 
to pH 4.0 by acetic acid and mixed with equal amount of buffer A containing 50 mM NaCl 
and 20 mM NaoAc at pH 5.0.  The sample was then loaded onto 100 mL of 
diethylaminoethyl (DEAE) column pre-equilibrated with buffer A, the loading was at 10 
mL/min by pump for overnight.  The DEAE column was washed with 1 liter of buffer A and 
then eluted with 350 mL buffer B containing 1 M NaCl and 20 mM NaOAc (pH 5.0) until 
the eluent was no longer brown.  The K5 polysaccharide was precipitated from eluent in 75% 
ethanol at -20 oC for overnight.  After spun down, the precipitate was resuspended into 40 
mL water, divided into two tubes and each mixed with 3.4 mL phenol/chloroform to remove 
 
 the protein and nucleic acid impurity, the aqueous part was precipitated in 75% ethanol at -20 
oC for overnight again, spun down and the precipitate was dissolved in 25 mL water.  The 
sample was mixed with 45,000 cpm tritium labeled heparosan and was then precipitated with 
saturated ammonium sulfate; the final concentration of the mixture is about 40% ammonium 
sulfate.  After removal of the supernatant from gel-like precipitate, the supernatant was 
precipitated again with 50% ammonium sulfate.  The gel-like precipitate was resuspended in 
water and dialyzed overnight against water with MWCO 12,000-14,000.  The sample was 
then loaded onto the DEAE column and purified; the fraction was monitored by the 3H 
radioactivity in the sample. After DEAE purification, the sample was extracted with 
phenol/chloroform again and precipitated in 75% ethanol for overnight at -20 oC.  The 
precipitate was dissolved in water and dried to weigh to obtain pure heparosan.  The yield of 
heparosan is about 100 mg/L of bacteria culture. 
 
Preparation of disaccharide acceptors 
Two disaccharide acceptors (GlcUA-AnMan 1 and GlcUA-AnMannose 2) were 
prepared from nitrous acid degraded heparosan as previously described (113, 139).  Briefly, 
heparosan (100 mg) was incubated with 10 mL of 2 M NaOH at 68 oC overnight to prepare 
the deacetylated heparosan.  The deacetylated heparosan was degraded to disaccharide with 
nitrous acid (1.5 M) at pH 4.5.  The resultant disaccharide was reduced by NaBH4 to yield a 
reducing terminal of 2, 5-anhydromannitol.  The resultant disaccharide (GlcUA-AnMan 1) 
was dialyzed against water using 1000 MWCO membrane (Spectrum) and served as the 
acceptor for untagged HS oligosaccharide.  In order to synthesize tagged disaccharide donor, 
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 a disaccharide (GlcUA-AnMannose 2) was also prepared from heparosan followed a very 
similar procedure as described above omitting the NaBH4 reduction step (Figure 20).  
 
 
 
Fig 20. Synthesis of disaccharides 1 and 2. 
 
Synthesis of [3H]-labeled UDP-N-acetylglucosamine 
Since radioactively-labeled UDP-sugars are expensive, our lab synthesized [3H]-
labeled UDP-N-acetylglucosamine (UDP-GlcN[3H]Ac) using a modified method from 
previous publication starting from [3H]acetate (151).  The reaction mixture contained 
acetyltransferase/N-acetylglucosamine-1-phosphate uridyltransferase (GlmU, 0.4 mg/mL), 50 
mM Tris-HCl (pH 7.0), 5 mM MgCl2, 200 μM dithiothreitol, 2.5 mM UTP, 20μM CoASH, 
200 μM sodium [3H]acetate (0.1 μCi/μL, 500 mCi/mmole purchased from MD Biomedicals)  
acetyl coenzyme A synthetase (0.1 mg/mL, Sigma-Aldrich), and 0.012 U/μL inorganic 
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 pyrophosphatase (Sigma-Aldrich).  Recombinant GlmU was expressed in E. coli and purified 
by a Ni-Agarose column. The reaction was incubated at 30 oC overnight with mild agitation. 
The concentration of UDP-GlcN[3H]Ac was determined with RPIP-HPLC as demonstrated 
by a [3H]-labeled peak coeluted with nonlabeled UDP-GlcNAc standard (Sigma-Aldrich) that 
has absorbance at 256 nm. 
 
 
 
Fig 21. Enzymatic synthesis of UDP-GlcN[3H]Ac. 
 
Preparation of UDP-N-trifluoroacetylglucosamine  
UDP-N-trifluoroacetylglucosamine (UDP-GlcNTFA) (152) is not commercially 
available, therefore we have developed a chemoenzymatic approach to synthesize this 
compound using GlmU, in a similar way previously described in the synthesis of UDP-
GlcN[3H]Ac.  The synthesis involved in preparing a GlcNTFA-1-phosphate (153) and 
coupling it with UDP (Figure 22).  Briefly, 11 mg of GlcNH2-1-phosphate (Sigma-Aldrich) 
was dissolved in 200 μL of anhydrous methanol and mixed with 60 μL of (C2H5)3N and 130 
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 μL S-ethyl trifluorothioacetate (Sigma-Aldrich).  The reaction was incubated at room 
temperature for 24 h.  The resultant GlcNTFA-1-phosphate was then converted to UDP-
GlcNTFA using GlmU in a buffer containing 46 mM Tris-HCl (pH 7.0), 5 mM MgCl2, 200 
μM dithiothreitol, 2.5 mM UTP and 0.012 U/μL inorganic pyrophosphatase (Sigma-Aldrich).  
The UDP-GlcNTFA was purified by removing proteins using centrifugal filters (10,000 
MWCO, Millipore) followed by the dialysis against water using 1000 MWCO membrane for 
4 h.  The product was confirmed by MS analysis.  The concentration was determined by a 
quantitative analysis with HPLC using a polyamine based column (PAMN column from 
Waters) and using UDP-GlcNAc as a standard.   
 
 
 
Fig 22. Chemoenzymatic synthesis of UDP-GlcNTFA.  Glucosamine-1-α-phosphate is commericially 
available from sigma.  The GlmU enzyme was cloned from E. coli K12. 
 
Section 2. Preparation of biosynthetic enzymes 
Expression of HS biosynthetic enzymes in E. coli 
We have made significant improvement on the enzyme-based synthesis of HS by 
enhancing the expression of enzymes.  HS biosynthetic enzymes are traditionally expressed 
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 in mammalian or insect cells.  We have expressed these enzymes in bacteria that coexpresses 
a chaperone protein, which dramatically reduces the difficulty in obtaining the enzymes in 
large quantities.  We used a bacterial cell line that coexpresses chaperone GroEL/GroES to 
achieve high levels of expression by taking advantage of the fact that the chaperone helps the 
proteins fold correctly.  These recombinant proteins have specific activities and substrate 
specificity comparable of those expressed in insect cells (Table 1). 
 
Expression of KfiA 
The expression of KfiA was carried out in BL21 star (DE3) cells (Invitrogen) 
carrying pGrp7 plasmid (Takara, Japan) coexpressing bacteria chaperone proteins, GroEL 
and GroES.  Briefly, bacteria cells was grown in LB medium supplemented with 50 μg/mL 
carbenicillin and 35 μg/mL chloramphenicol at 37 oC until OD600 reached 0.6, the 
temperature was then dropped to 22 oC and 0.1 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG) and 1 mM sterilized arabinose was added to induce the expression KfiA and 
chaperone respectively.  The culture was shaken overnight at 22 oC and the bacteria were 
harvested and lyased by sonication in a buffer containing 25 mM Tris-HCl, pH 7.5, 30 mM 
immidazole and 500 mM NaCl.  The protein was loaded onto a Ni-sepharose 6 Fast Flow 
column (0.75 x 10 cm, Amersham) pre-equilibrated with buffer A containing 25 mM Tris-
HCl, pH 7.5, 30 mM immidazole and 500 mM NaCl.  After washed with buffer A, the 
protein was eluted with 1 mL buffer B containing 25 mM Tris-HCl, pH 7.5, 250 mM 
immidazole and 500 mM NaCl.  The purity of protein was analyzed by precast 10% SDS-
PAGE (BioRad).  Briefly, samples were diluted with an equal volume of sample buffer 
containing 2% SDS (BioRad) and 200 mM Tris-HCl, pH 6.8.  After the gels were run at 
 54
 110V for 1 hour, the gels were stained for 30 mins with 0.4 % coomassie blue. Gels were 
destained using 10% acetic acid (113).  
 
Expression of PmHS2 
PmHS2 was expressed as an N-terminal fusion to 6 × His using a PET-15b vector 
(Novagen).  The expression of PmHS2 was carried out in BL21 star (DE3) cells (Invitrogen) 
coexpressing bacteria chaperone proteins, GroEL and GroES.  The bacteria were harvested 
and lyased by sonication in buffer A containing 25 mM Tris-HCl (pH 7.5), 500 mM NaCl 
and 30 mM imidazole.  The protein was loaded onto a Ni-Sepharose 6 Fast Flow column 
(0.75 x 10 cm, Amersham) pre-equilibrated with buffer A containing 25 mM Tris-HCl, pH 
7.5, 30 mM immidazole and 500 mM NaCl.  After washed with buffer A, the protein was 
eluted with buffer B containing 25 mM Tris-HCl, pH 7.5, 250 mM immidazole and 500 mM 
NaCl.  
 
Expression of NST 
NST was expressed according to previous report (88).  NST was expressed in E. coli.  
For NST, a glutathione S-transferase fusion was prepared and purified by a glutathione 
Sepharose column (GE Healthcare).  The protein, although carrying a glutathione S-
transferase, exhibited high level of N-sulfotansferase activity, thus, no cleavage of the GST-
tag is necessary. 
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 Table 1. List of HS biosynthetic enzymes expressed in E. coli 
Enzyme Bacterial expression cells fusion protein Yield 
(mg/L) 
NDST2 Rosetta-gami-B with GroEL MBP-fusion protein 2  
NDase1a Rosetta-gami-B with GroEL Thioredoxin-fusion protein 5  
NDase2a Rosetta-gami-B with GroEL MBP-fusion protein 10  
NDase3a Rosetta-gami-B with GroEL Thioredoxin-fusion protein 5 
NSTb BL21 GST-fusion protein 20 
Epi Rosetta-gami-B with GroEL MBP-fusion protein 15 
2OST Rosetta-gami-B MBP-fusion protein 12 
6OST1 Rosetta-gami-B with GroEL MBP-fusion protein 14 
6OST2 Rosetta-gami-B with GroEL (His)6-fusion protein 4 
6OST3 Rosetta-gami-B with GroEL (His)6-fusion protein 6 
3OST1 BL21(DE3)RIL (His)6-fusion protein 8 
3OST3 BL21(DE3)RIL (His)6-fusion protein 3 
3OST5 Rosetta-gami-B with GroEL (His)6-fusion protein 8 
KfiA BL21 Star with GroEL (His)6-fusion protein 10 
pmHS2 BL21 Star (His)6-fusion protein 20 
 
a. NDase1, 2 and 3 represents the N-deacetylase domain of NDST1, NDST2, and NDST3, respectively. 
b. NST represents the N-sulfotransferase domain of NDST1. 
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 Expression of C5-epi 
The full length cDNA of C5-epimerase was a gift from Dr. Rosenberg from MIT 
(124).  The catalytic domain of human C5-epi (E53-N609) was firstly cloned into pMAL-c2X 
vector (New England Biolabs) using the BamH1 and HindIII restriction enzyme sites to 
generate a maltose-binding protein (MBP)-epimerase fusion protein.  C5-epi was expressed in 
origami-B cells (Novagen) carrying pGro7 plasmid (Takara, Japan) which expresses 
chaperone protein GroL and GroES.  The bacteria were grown in LB medium supplemented 
with 12.5 μg/mL tetracycline, 15 μg/mL kanamycin, 50 μg/mL carbenicillin, 2 mg/mL 
glucose and 35 μg/mL chloramphenicol at 37 oC until OD600 reached 0.6, the temperature 
was then dropped to 22 oC and 0.1 mM IPTG and 1 mM sterile arabinose was added to 
induce the expression of C5-epi and chaperone respectively.  The protein was purified by an 
amylase-agarose column following the protocol provided by the manufacturer (New England 
Biolabs).   
 
Expression of 2OST 
The full length cDNA of 2OST was a gift from Dr. Rosenberg from MIT (124).  The 
catalytic domains of 2OST of Chinese hamster ovary (CHO, Arg51-Asn356) was cloned into 
pMAL-c2X vector (New England Biolabs) using the BamH1 and HindIII restriction enzyme 
sites to generate a maltose-binding protein (MBP)-epimerase fusion protein.  Expression of 
2OST was achieved in Rosetta-gami B (DE3) cells (Novagen) using a standard procedure.  
Briefly, the bacteria were grown in LB medium with 2 mg/mL glucose, 12.5 μg/mL 
tetracycline, 15 μg/mL kanamycin, 50 μg/mL carbenicillin and 35 μg/mL chloramphenicol at 
37 oC until OD600 reached 0.6, the temperature was then dropped to 22 oC and 0.1 mM 
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 IPTG and 1 mM sterile arabinose was added to induce the expression of 2OST and 
chaperone respectively (124).  The protein was purified by an amylase-agarose column 
following the protocol provided by the manufacturer (New England Biolabs).   
 
Expression of 6OST1 and 6OST3 
6OST1 and 6OST3 were expressed in E. coli. The catalytic domains of 6OST1 of 
mouse (His53-Trp401) was cloned into pMAL-c2X vector (New England Biolabs) using the 
BamH1 and HindIII restriction enzyme sites to generate a maltose-binding protin (MBP)-
epimerase fusion protein (124).  The full length cDNA of 6OST1 was a gift from Dr. Kimata 
(Aichi University, Japan).  Expression of 6OST1 was achieved in Rosetta-gami B (DE3) 
cells (Novagen) using a standard procedure.  Briefly, the bacterica were grown in LB 
medium with 2 mg/mL glucose, 12.5 μg/mL tetracycline, 15 μg/mL kanamycin, 50 μg/mL 
carbenicillin and 35 μg/mL chloramphenicol at 37 oC until OD600 reached 0.6, the 
temperature was then dropped to 22 oC and 0.1 mM IPTG and 1 mM sterile arabinose was 
added to induce the expression of 6OST1 and chaperone, respectively.  The protein was 
purified following the protocol provided by the manufacturer (New England Biolabs).    
Expression of 6OST3 was somewhat different from 6OST1 (125).  The catalytic 
domain of 6OST3 of mouse (Pro121-Pro450) was cloned into pMAL-c2X vector (New 
England Biolabs) from a mouse brain Quick clone cDNA library (BD Biosciences).  
Expression of 6OST3 was achieved in origami-B cells (Novagen) carrying pGro7 plasmid 
(Takara, Japan) which expresses chaperone protein GroL and GroES.  The cells were grown 
in LB medium with 2 mg/mL glucose, 12.5 μg/mL tetracycline, 15 μg/mL kanamycin, 50 
μg/mL carbenicillin and 35 μg/mL at 37 oC until OD600 reached 0.4-0.7, the temperature 
 58
 was then dropped to 22 oC and 0.1 mM IPTG and 1 mM sterile arabinose was added to 
induce the expression of 6OST3 and chaperone respectively.  The protein was purified by an 
amylase-agarose column following the protocol provided by the manufacturer (New England 
Biolabs).   
 
Expression of 3OST1 
The expression of 3OST1 was also carried out in E. coli.  The catalytic domain of 
mouse 3OST1 (Gly48-His311) (154) was amplified from m3OST1-pcDNA3 with 5’ 
overhang containing an NdeI restriction enzyme site and 3’ overhang containing an EcoRI 
restriction enzyme site.  This construct was inserted into the pET28a vector (Novagen) using 
the NdeI and EcoRI restriction enzyme sites to produce a His6-tagged protein.  The resultant 
plasmid (b3OST1-pET28) was sequenced in the DNA sequencing core facility (University of 
North Carolina) to confirm the reading frame and the lack of mutations within the coding 
region.  The plasmid was then transformed into BL21 (DE3) RIL cells (stratagene) to express 
3OST1.  Briefly, bacteria cells containing the b3OST1-pET28 were grown in LB media with 
50 μg/mL kanamycin at 37 oC until the OD600 reached 0.6-0.8; the temperature was then 
dropped to to 22 oC and 0.2 mM IPTG was added to induce the expression and the cells were 
allowed to shake overnight.  The bacteria were harvested and lyased by sonication in buffer 
A containing 25 mM Tris-HCl, pH 7.5, 10 mM immidazole and 500 mM NaCl.  The protein 
was loaded onto a Ni-Sepharose 6 Fast Flow column (0.75 x 10 cm, Amersham) pre-
equilibrated with buffer A containing 25 mM Tris-HCl, pH 7.5, 30 mM immidazole and 500 
mM NaCl.  After washed with buffer A, the protein was eluted with buffer B containing 25 
mM Tris-HCl, pH 7.5, 250 mM immidazole and 500 mM NaCl. 
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 Expression of GlmU 
Recombinant GlmU was expressed in E. coli and purified by a Ni-Agarose 6 
FastFlow column.  Briefly, cells was grown in LB medium with 50 μg/mL carbenicillin and 
35 μg/mL at 37 oC until OD600 reached 0.6, the temperature was then dropped to 22 oC and 
0.1 mM IPTG and 1 mM sterile arabinose was added to induce the expression GlmU and 
chaperone respectively.  The culture was shaked overnight at 22 oC and the bacteria were 
harvested and lyased by sonication in a buffer containing 25 mM Tris-HCl, pH 7.5, 30 mM 
immidazole and 500 mM NaCl.  The protein was loaded onto a Ni-sepharose 6 Fast Flow 
column (0.75 x 10 cm, Amersham) pre-equilibrated with buffer A containing 25 mM Tris-
HCl, pH 7.5, 30 mM immidazole and 500 mM NaCl.  After washed with buffer A, the 
protein was eluted with 1 mL buffer B containing 25 mM Tris-HCl, pH 7.5, 250 mM 
immidazole and 500 mM NaCl.  
 
Section 3. Preparation of N-sulfo tagged octasaccharide library 
Preparation of tagged disaccharide  
The disaccharide (2) starting material was prepared from nitrous acid degraded 
heparosan as previously described to prepare octasaccharide library 3-6.  
To synthesize fluorous-tagged disaccharide GlcUA-AnMan-Rf (7), the disaccharide 
(2) was incubated with 2 equivalent 4-(1H, 1H, 2H, 2H-perfluoropentyl) benzylamine 
hydrochloride (Fluorous Technologies) and NaBH3CN (10 equiv.) in 75% MeOH, pH 4.5, 
overnight at room temperature (155).  The fluorous tag allowed isolation of the product with 
a FluoroFlash affinity chromatography and has absorbance at 260 nm that facilitated HPLC 
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 analysis during the preparation. The resulting tagged disaccharide was purified by 
FluoroFlash column.  The sample was loaded to a PD-10 column (GE healthcare) containing 
fluorous silica gel (40 μm, fluorous Technologies).  The column was pre-equibrated with 
water.  After the samples were loaded, the column was initially washed with 100% water to 
remove protein and UDP-sugars, then the tagged oligosaccharides were eluted with 100% 
methanol.  The tagged disaccharide was further purified by paper chromatography using 
Whatman 3 MM chromatography paper (Fisher) and developed with 100% acetonitrile.  The 
tagged disaccharide was spotted at the bottom of the paper and the paper chromatography 
was carried out into a solvent tank.  The paper chromatography was completed when the 
acetonitrile reach to the top of the paper.  The original spot was cut out and tagged 
disaccharide was eluted with methanol. After paper chromatography, the tagged disaccharide 
was finally purified by a C18 column (0.46 × 25 cm, Thermo scientific) under reverse phase 
HPLC (RP-HPLC) conditions.  The column was eluted with a linear gradient from 90% 
solution A (0.1% TFA in water) to 50% solution A for 40 min at a flow rate of 0.5 mL/min, 
then followed by an additional wash for 20 min with 100% solution B (0.1% TFA in 
acetonitrile) at a flow rate of 0.5 mL/min.  The tagged glucose was prepared in 7:3 DMSO/ 
acetic acid at 65 oC overnight and was purifed by the same procedure. 
 
Preparation of fluorous tagged octasaccharide backbones 
To prepare the fluorous-tagged octasaccharide backbones, the synthesis was started 
with the fluorous-tagged disaccharide (7).  The size of oligosaccharide backbone was 
controlled by the number of KfiA and PmHS2 modifications.  In each monosaccharide 
incorporation step, we supplied the reaction mixture with either KfiA or PmHS2 and 
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 appropriate UDP-monosaccharide donor.  As a result, only one sugar residue was transferred 
into the backbone.  At the end of each round of modification, fresh PmHS2 or KfiA enzymes 
was added to transfer a second monosaccharide in the next cycle.  FluoroFlash column was 
used to purify the products from unreacted UDP-monosaccharides and enzymes.   
 
Selective de-N-trifluoroacetylation of GlcNTFA units 
Various amounts of tagged oligosaccharides (50 to 100 μg) were dried and re-
suspended in a solution (500 μL) containing CH3OH, H2O and (C2H5)3N (v/v/v = 2:2:1).  The 
reaction was incubated at 37 oC overnight.  The samples were dried and reconstituted in H2O. 
The de-N-trifluoroacetylated tagged oligosaccharides were then purified by a C18 column 
(0.46 × 25 cm, Thermo scientific) under reverse phase HPLC (RP-HPLC) conditions to 
remove the protein contamination.  The column was eluted with a linear gradient from 90% 
solution A (0.1% TFA in water) to 50% solution A for 40 min at a flow rate of 0.5 mL/min, 
then followed by an additional wash for 20 min with 100% solution B (0.1% TFA in 
acetonitrile) at a flow rate of 0.5 mL/min. Selective de-N-trifluoroacetylation of untagged 
oligosaccharide was similar, the reaction was incubated at room temperature overnight.  
Unlike the tagged oligosaccharide, the further HPLC purification for untagged 
oligosaccharide is not necessary. 
 
Preparation of N-sulfo tagged octasaccharides 3-6 
After purification by a C18 column under RP-HPLC conditions and dried, the 
octasaccharides were then N-sulfated by NST.  Various amounts of tagged octasaccharide 
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 (20 to 30 μg) were incubated with NST (80 μg), and PAPS (2 equiv.) in 300 μL buffer 
containing 50 mM MES (pH 7.0) and 1% Triton X-100.  The reactions were incubated at 37 
oC.  After overnight, another 80 μg fresh NST enzyme was added and was incubated for 
additional 8 h.  The tagged N-sulfo-octasaccharides were purified by RP-HPLC as described 
above. 
 
Section 4. Preparation of untagged oligosaccharides 
Preparation of HS untagged oligosaccharide backbones 
Both untagged and fluorous-tagged oligosaccharide backbones were prepared using 
very similar conditions although the fluorous-tagged oligosaccharides were purified by 
FluoroFlash column (Fluorous Technologies), while untagged oligosaccharides were purified 
by BioGel P-10 (BioRad). 
Disaccharide (GlcUA-AnMan, 1) (4.5 μmoles) was incubated with UDP-GlcNTFA 
3.9 μmoles and  KfiA (0.1 mg) in a 1 mL buffer containing 25 mM Tris-HCl (pH 7.2), 10 
mM MgCl2.  The reaction was incubated at room temperature overnight.  An aliquot of 
reaction mixture was analyzed by PAMN-HPLC to ensure >95% of UDP-GlcNTFA was 
converted to UDP.  Upon the complete consumption of UDP-GlcNTFA, PmHS2 (0.5 mg) 
and UDP-GlcUA (4 μmoles) were added into the reaction mixture for additional 4-5 h at 
room temperature.  Another aliquot of PmHS2 (0.5 mg) and UDP-GlcUA (4 μmoles) was 
added to drive the transfer of GlcUA unit to completion.  It is important to note that PmHS2 
has both activities in transferring GlcNAc (or GlcNTFA in less efficiency) and GlcUA.  
Without removal of UDP-GlcNTFA, PmHS2 led to polymerization or uncontrollable 
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 oligomerization of the saccharide, resulting in low yield of the tetrasaccharide product.  The 
reaction mixture was resolved on a BioGel P-10 (0.75 × 200 cm), which was equilibrated 
with 20 mM Tris (pH 7.5) and 1 M NaCl at a flow rate of 4 mL/h.  The elution position of the 
tetrasaccharide was determined by a 3H-labeled tetrasaccharide.  The product was dialyzed 
against water using 1000 MWCO membrane.  The reaction cycle was repeated four and five 
times to prepare the decasaccharide 8, undecasaccharide 9, and dodecasaccharide 10.   
 
Preparation of N-sulfo decasaccharide 11, undecasaccharide 12 and dodecasaccharide 13 
N-sulfation of oligosaccharide was carried out by incubating the de-N-
trifluoroacetylated oligosaccharide substrates with NST and PAPS.  The reaction mixture 
typically contained 6 μg de-N-trifluoracetylated decasaccharide, undecasaccharide and 
dodecasaccharide, 80 μM PAPS, 50 mM MES, pH 7.0, 1.0% Triton X- 100 (v/v) and 4 μg of 
NST in a total volume of 300 μL.  The reaction mixture was incubated at 37 oC overnight.      
The oligosaccharides were purified by a DEAE column.  The reaction mixture (300 
μL) was mixed with 1 mL of 0.01% Triton X-100 buffer at pH 5.0 containing 150 mM NaCl, 
50 mM NaOAc, 3 M Urea, 1 mM EDTA, then followed by four washes with the same buffer, 
each time 1 mL, and was eluted with 1 M NaCl in 0.001% Triton X-100 buffer.   The 
purified oligosaccharides were dialyzed using MWCO 3500 membrane and dried.  Final 
product was further purified by a DEAE-HPLC column (0.46 × 7.5 cm, Tosohaas).   
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 Preparation of N-sulfo-6-O-sulfo decasaccharide 14 and dodecasaccharide 15 
The 6-O-sulfo oligosaccharides were prepared by incubating 6OST1 and 6OST3 with 
N-sulfo oligosaccharide substrates.  The reaction mixture contained 6 μg N-sulfated 
decasaccharide (11) and dodecasaccharide (13), 80 μM PAPS, 50 mM MES, pH 7.0, 0.5% 
Triton X-100 (v/v), 4 μg of 6OST1 and 4 μg of 6OST3 proteins in a total volume of 300 μL.  
The reaction mixture was incubated at 37 oC overnight.  Prepraration of tagged N-sulfo-6-O-
sulfo oligosaccharides is followed the same procedure. The tagged oligosaccharides were 
purified by RP-HPLC as described above. 
 
Preparation of N-sulfo-3, 6-O-sulfo decasaccharide 16 and dodecasaccharide 17 
The 3-O-sulfo oligosaccharides were prepared by incubating oligosaccharide 
substrates with 3OST1 and 3OST5 enzymes.  The reaction mixture contained 6 μg 
decasaccharide 14 or dodecasaccharide 15, 80 μM PAPS, 50 mM MES, pH 7.0, 10 mM 
MnCl2, 5 mM MgCl2, and 0.5% Triton X- 100 (v/v) and 4 μg of 3OST1  and 4 μg of 3OST5 
proteins in a total volume of 300 μL.  The reaction mixture was incubated at 37 oC for 8 h.  
The products were purified by DEAE-HPLC as described above. 
 
Section 5. Structural analysis 
Nitrous acid degradation of untagged oligosaccharides 
The untagged N-sulfated/N, O-sulfated oligosaccharide was degraded by low pH 
nitrous acid degradation. Briefly, about 100,000 cpm oligosaccharide was dried and 
dissolved in 20 μL ddH2O.  20 μL 0.5M H2SO4 was mixed with 20 μL 0.5M Ba(NO2)2 and 
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 spun down.  The supernatant was added to the sample and incubated on ice for 30 min with 
occasional vortex.  The reaction was quenched by a mixture of 20 μL 1 M Na2CO3 and 1 M 
NaHCO3 (v/v 1:1).  The resultant disaccharide was mixed with 0.5 μL of 5% phenol red and 
purified by BioGel P-10 (BioRad) column.  The resultant disaccharide was dialyzed against 
double-distilled water using 1000 MWCO membrane (Spectrum) for 5 hours and ready for 
HPLC analysis 
  
HPLC analysis 
Several HPLC conditions were used depending on the nature of the analytes.  To 
conduct the analysis of disaccharides resulted from nitrous acid or heparin lyases-degraded 
oligosaccharides, ion-pairing reverse phase (RPIP)-HPLC was employed.  Here, a C18 
column (0.46 × 25cm, Vydac) was eluted with a stepwise gradient of acetonitrile in the 
solution of 38 mM NH4H2PO4, 2 mM H3PO4, 1 mM tetrabutyl ammonim phosphate 
monobasic (Sigma) for disaccharide analysis of oligosaccharides 14, 15, 16.  Alternatively, 
the C18 column was eluted with the solution containing 10 mM NH4H2PO4, 0.5 mM H3PO4, 1 
mM tetrabutyl ammonim phosphate monobasic for disaccharide analysis of dodecasaccharide 
17, first 7% (v/v) for 30 min, then 15% (v/v) for 15 min, and 19.5% (v/v) for 75 min.  
DEAE-HPLC (Tosohaas) was utilized to purify and analyze oligosaccharides with sulfo 
groups.  The DEAE- HPLC column was eluted with a linear gradient of NaCl in 20 mM pH 
7.0 Tris-HCl buffer from 0 to 0.5 M for 60 min for N-sulfated oligosaccharides (11-13).  
Alternatively, the column was eluted with gradient NaCl from 0 to 1 M for 60 min for 6-O-
sulfated and 3-O-sulfated oligosaccharides (14-17), then, followed by an additional wash 
with 1 M NaCl in 20 mM pH 7.0 Tris-HCl buffer at a flow rate of 0.4 mL/min.  
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 Microdialysis of oligosaccharides 
In order to improve the sensitive of the analysis by MS, the synthesized 
oligosaccharides were subjected to microdialysis to remove the salt.  The dialysis was carried 
out using hollow fiber dialysis tubing (MWCO 13,000 Da, Spectrum) against 20 mM 
ammonium acetate. 
 
Liquid chromatography linked mass spectrometry analysis 
Liquid chromatography linked mass spectrometry (LC-MS) analyses were performed 
at the ADME Mass Spectrometry Center on an Agilent 1100 HPLC-MSD-Trap.  Backbone 
oligosaccharides were injected onto an Aquasil C18 column (3 μm 50 × 2.1 mm, Thermo).  A 
gradient of acetonitrile with a flow of 0.4 mL/min was directed into the ion trap mass 
spectrometer.  The gradient consisted of an initial 5 min hold at 90% aqueous (0.1% formic 
acid in water), a change to 90% organic (0.1% formic acid in acetonitrile) over 2 min, a 2 
min hold at 90% organic, a change to 90% aqueous over 2 min, and a 4 min re-equilibration 
at 90% aqueous.  Experiments were performed in positive ionization mode for untagged 
backbone oligosaccharide.  Alternatively, the analyses were performed in negative ionization 
mode for tagged backbone oligosaccharides.  Under both conditions, the electrospray source 
set to 3000V and 350 oC, and the compound stability set to 30%.  Nitrogen was used for both 
nebulizer (8L/min) and drying gas (45 psi).  Helium was used for collision-induced 
dissociation.  The MS and MS/MS data were acquired and processed using Bruker Trap 
Software 4.1.  All product ions in MS/MS data were labeled according to the Domon-
Costello nomenclature (156). 
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 Mass spectrometry analysis 
Oligosaccharides with sulfo groups were dissolved in 70% acetonitrile and 10 μM 
imidazole.  A syringe pump (Harvard Apparatus) was used to introduce the sample via direct 
infusion (10μL/min) into an Agilent 1100 MSD-Trap at the ADME Mass Spectrometry 
Center.  Experiments were performed in negative ionization mode with the electrospray 
source set to 3000V and 200 C, and the compound stability set to 30%.  Nitrogen was used 
for both nebulizer (5 L/min) and drying gas (15 psi).  Helium was used for collision-induced 
dissociation.  The MS and MS/MS data were acquired and processed using Bruker Trap 
Software 4.1.  All product ions in MS/MS data were labeled according to the Domon-
Costello nomenclature. 
 
Section 6. Activity analysis 
Antithrombin binding assay  
Antithrombin (AT) binding assay was done as previously report (123).  Briefly, [35S] 
labeled oligosaccharide sample (approximately 4000 cpm) was mixed with 100 μL of a 
buffer containing 10 mM Tris (pH 7.5), 150 mM NaCl, 1mM Me2+ (Mn2+, Mg2+, and Ca2+), 
10 μM dextran sulfate, 0.1 mg/mL antithrombin, 0.02% NaN3 and 0.004% Triton X-100.  
The solution was incubated at room temperature for 30 min and 200 μL slurry of aged ConA-
Sepharose gel was added.  After shaking at room temperature for 3-4 hours, the solution was 
spun down and the supernatant was removed.  The bead was then washed three times with a 
buffer containing 10 mM Tris (pH 7.5), 150 mM NaCl, and 0.004% Triton X-100.  The 
entire bead was taken to measure the radioactivity.  
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Determination of the binding affinity of oligosaccharides to AT 
The dissociation constant (Kd) of each sample and AT was determined using affinity 
co-electrophoresis (157).  Approximately 4000-5000 cpm of antithrombin-binding 35S-
labeled oligosaccharide was loaded per lane with zones of AT at concentrations 0 to 12.5 μM.  
The gel was performed at 400 mA for 2 h, dried and analyzed on a PhosphoImager 
(Amersham Biosciences, Storm 860).  The retardation coefficient was calculated at R = (M0-
M)/M, where M0 is the mobility of the polysaccharide through the zone without AT, and M is 
the mobility of the oligosaccharide through each separation zone.  The retardation coefficient 
was then plotted against the retardation coefficient divided by its respective concentration of 
AT. The slope of the line represents -1/Kd. 
Chapter III SYNTHESIS OF N-SULFO OCTASACCHARIDE LIBRARY 
 
Section 1. Introduction 
The biosynthesis of HS is not a template-controlled process thus the level of sulfation and the 
positioning of IdoUA residues are thought to depend on the substrate specificities of O-
sulfotransferase and C5-epi.  The placement of the GlcNS residue is believed to be critical in 
modulating susceptibility to the subsequent O-sulfation and epimerization (22).  Therefore, 
synthesis of oligosaccharides having defined N-sulfation positions is an important step in 
developing a route for the controlled enzymatic synthesis of HS oligosaccharides and 
polysaccharides.  However, it is unclear how to introduce a GlcNS residue into a specific 
position using NDST due to limited knowledge of its substrate specificity.  Here, we tried to 
develop a general approach to synthesize octasaccharides with GlcNS residues at specific 
locations.  We used KfiA and pmHS2 to build the oligosaccharide backbone.  Since KfiA 
does not utilize UDP-GlcNH2 as a donor substrate, an unsubstituted glucosamine residue 
cannot be directly introduced into an octasaccharide backbone.  We have used an unnatural 
monosaccharide donor, UDP-trifluoroacetylglucosamine (UDP-GlcNTFA), to empower the 
placement of a GlcNS residue at any desired position in the oligosaccharide backbone. By 
selecting either UDP-GlcNAc or UDP-GlcNTFA, we are able to position the GlcNH2 residue 
in an oligosaccharide.  The GlcNH2 residue is then readily converted to GlcNS by NST. 
 
 The synthesis started from a disaccharide. Because the synthesis of HS 
oligosaccharides requires numerous steps, a method for easy separation with high recovery 
yield of product is critical for the multi-step de novo synthesis.  Traditional purification 
methods for carbohydrates by size-exclusion column or reverse phase ion pairing (RPIP)-
HPLC are time consuming, and the yield is only around 50% at each purification step.  
Developing an affinity-tag based purification method is highly significant for carbohydrate 
synthesis.  Therefore, it is endeavored to develop an affinity-tag based approach.   
The purification of reaction mixture is time-consuming process in the synthesis, 
especially in the throughput synthesis for large number of compounds.  Affinity tagging is a 
general strategy for the purification of reaction mixture.  One of these strategies is fluorous 
affinity tag.  Fluorous tag based synthesis employs perfluoroalkyl group (Rf) as affinity tags. 
This technology allows solution phase synthesis.  The advantages of fluorous tag include fast 
reaction, chemically stable, easy separation and flexibility in reaction scale (158, 159).  In 
fluorous tagged based synthesis, fluorous tags are only applied for separation while have no 
interaction with the function groups (158, 159).  One fluorous tagged based separation is 
fluorous solid-phase extraction (160, FSPE).  In FSPE, the separation is based on strong and 
highly selective fluorine-fluorine interactions between the flurous tag and fluorous silica gel. 
The samples without fluorous tag will be eluted by fluorophobic wash, which is generally 
low percentage of methol while fluorous compound will be stick on the fluorous silica gel 
and is eluted by fluorophilic wash, which is generally 100% methol.  A fluorous affinity tag 
technique has been reported for the chemical synthesis of combinatorial libraries and total 
synthesis of complex natural products, such as pyridovericin, and mappicine (161-164). For 
example, Curran and his colleagues have reported a fluorous mixture synthesis.  In this study, 
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 a series of compounds was tagged with a series of fluorous tags with different length.  These 
compounds were mixed and conducted to the synthesis of a mixture of enantiomers of 
analogs of mappicine.  After mixture synthesis, these analogs were easily separated by 
fluorous HPLC based on the fluorine content (161). 
 Fluorous tag approach has also been applied in the synthesis and microarray analysis 
of carbohydrate (165, 166).  For example, Pohl and her colleagues have synthesized fluorous 
tagged carbohydrates which are purified by fluorous tag.  Furthermore, the tagged 
carbohydrates can be directly spotted onto fluorous slides to make carbohydrate microarrays 
for screening (166).  
Fluorous tag techniques have an additional advantage for structure analysis by mass 
spectrometry (165, 167).  The flurous tags are stable, making MS spectra less complicated. 
Furthermore, fluorous tagged molecules are easily ionized and have molecular ions that are 
readily identified (165).  Therefore, in this Chapter, the use of fluorous tagged 
oligosaccharide substrates has been demonstrated to carry out these studies.  
 
Section 2. Optimization of fluorous tagged saccharides 
Preparation of tagged glucose 
To prove the feasibility of tagging oligosaccharides, glucose was used as a model 
compound in searching for the optimal preparation procedure.  3 mg glucose mixed with 
100,000 cpm 3H-glucose was used to prepare 5.7 mg of tagged glucose (18) as described in 
Chapter II.  The reaction was monitored by the incorporated tritium with a yield of 73%.  
Nonradioactive tagged glucose was also prepared for MS analysis.  The MS analysis revealed 
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 a molecular weight of 467.2, very close to the calculated molecular weight 467.4 (Figure 23). 
This study demonstrated that the tagged oligosaccharide could be prepared in milligram scale 
with ready purification. 
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Fig 23. Synthesis and characterization of tagged glucose 18.  Panel A shows the preparation of tagged 
glucose 18.  Panel B shows the MS spectrum of tagged glucose 18.  The MS analysis is conducted by ESI-
MS in positive mode.  MS analysis revealed a molecular weight of 467.1 Da, close to the calculated value 
of 467.4 Da. 
 
Removal of fluorous tag by catalytic hydrogenolysis  
The fluorous tag should be removed from the HS oligosaccharide product when the 
synthesis is completed.  To prove feasibility, tritium labeled tagged glucose was chosen as a 
model compound.  The tag was cleaved with nearly 100% yield when the tagged glucose was 
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 treated with 5% formic acid in 50% MeOH, using Pd/C as catalyst (Figure 24).  The results 
suggest that it is possible to remove the fluorous tag after sulfated oligosaccharidess are 
synthesized. 
 
Pd/C, 5% HCOOH
50% MeOH/H2O, rt, O/N
OH
NH2
OH
HO
HO
H2C
OH
OH H
N
OH
HO
HO
H2C
OH C3F7
3H labeled tagged glucose 18 19, ~ 100%  
 
Fig 24. Catalytic hydrogenolysis to remove the fluorous tag.  3H-label is shown in red.  The reaction is 
monitor by the incorporated tritium.  
 
Optimization of fluorous tag  
It is known that the fluorous compound dose not dissolve well in water, while the 
enzymatic reaction has to be in aqueous solution.  One approach to improve the water 
solubility of the tagged oligosaccharide is to use a short tag without compromising the 
binding affinity to the FluoroFlash column.  To examine the binding affinity, the tritium-
labeled gluose was coupled with fluorous tag of different length: C3F7, C4F10, C6F13 and 
C8F17 (Fluorous Technologies).  The tagged glucose was loaded on the fluorous column and 
eluted with a MeOH gradient.  The binding and eluting efficiency from a fluorous column 
was monitored according to the 3H count, provided that 3H labeled glucose was employed in 
this experiment.  It was found that C3F7-tagged glucose bound to the column until 60% 
MeOH, while C4F10-tagged glucose and C6F13-tagged glucose bind to the fluorous column 
until 70% MeOH.  All tagged glucoses regardless the number of CF2 number, bound to the 
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 fluorous column.  The tagged glucose maintained the binding to the column when the column 
was washed with 100% water.  The tagged glucose was eluted by 100% MeOH. Our data 
suggest that the tagged glucose can bind to fluorous column and be eluted efficiently by 
choosing the appropriate solutions.  The results are summarized on Table 2.  Because the 
C3F7 tagged glucose has the best water solubility among the tested compounds and has 
adequate affinity to the fluorous column, the C3F7 tag (Rf) was chosen to proceed with the 
subsequent work.  
 
Table 2. Binding affinity of fluorous tag  
 
MeOH% C3F7 C4F10 C6F13 C8F17 
0% not eluted not eluted not eluted not eluted 
50% not eluted not eluted not eluted not eluted 
60% eluted not eluted not eluted not eluted 
70% eluted eluted eluted not eluted 
80% eluted eluted eluted not eluted 
100% eluted eluted eluted eluted 
 
Section 3. Susceptibilities of acceptors and donors to glycotransferases 
Preparation of tagged disaccharide 
Tagged disaccharide 7 was prepared as described in Chapter II.  The molecular 
weight of the resulting product was confirmed by ESI mass spectrometry as shown in Figure 
25 B.  It is very important to note that it is essential to obtain pure tagged disaccharide for 
subsequent synthesis since unreacted tags inhibited the activity of glycotransferase.  Tagged 
disaccharide could be prepared on a milligram scale, sufficient enough for further biological 
studies. 
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Fig 25. Synthesis and characterization of tagged disaccharide 7.  Panel A shows the preparation of tagged 
disaccharide 7.  Panel B shows the MS spectrum of disaccharide 7.  The MS analysis is conducted by ESI-
MS in negative mode.  MS analysis revealed a molecular weight of 625.6 Da, very close to the calculated 
value of 625.5 Da. 
 
Susceptibilities of tagged disaccharide to KfiA and pmHS2 
To demonstrate that tagged disaccharides serve as the substrates for heparosan 
biosynthetic enzymes KfiA and pmHS2, the tagged disaccharides were first subjected to the 
modification of KfiA by using a tritium-labeled UDP- GlcN[3H]Ac.  It was found that KfiA 
could efficiently transfer GlcNAc group to the tagged disaccharide 7.  The resulting tagged 
trisaccharide 20 was purified by a FluoroFlash column with at least 75% efficiency.  The 
reaction was monitored by the incorporated GlcN[3H]Ac.  The yield is calculated based on 
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 the recovery of [3H] counts.  Similarly, tagged trisaccharide 20 was subjected to the 
modification of pmHS2, by using non-radioactive labeled UDP-GlcUA.  We found that 
pmHS2 could transfer a GlcUA group to the tagged trisaccharide with high effiency, and the 
resulting [3H] labeled tagged tetrasaccharide 21 were purified by a fluorous column.  After 
two additional cycles, we prepared tritium-labeled pentasacchride 22 and hexasaccharide 23, 
and the molecular size of this hexasaccharide 23 was determined by the migration position on 
a Bio-Gel P10 (Bio-Rad) column.  Furthermore, only a single symmetric 3H-peak was 
observed after P-10 column analysis, suggesting that the hexasacchride is pure (Figure 26B).  
Meanwhile, nonradioactive hexasaccharide 23 was resynthesized using same synthetic route.  
MS analysis revealed a molecular weight of 1384.2 Da in close agreement to the calculated 
value of 1384.1 Da. MS/MS analysis confirmed the position of the GlcNAc residues from the 
two characteristic daughter ions, Y3 (m/z, 827.3) and B3 (m/z, 554.1), products of the 
cleavage of an internal glycosidic linkage.  The product ions in MS/MS data were labeled 
according to the classic Domon-Costello nomenclature (Figure 27).  The data conclude that 
we could generate a pure tagged hexasaccharide with high efficiency and purity. 
 
 
 77
 4 0 5 0 6 0 7 0 8 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
3 0 0 0
1
2 3
(1) Hexa-, (2) Tetra-, (3) Disaccharide
B.
A.
Fraction Number of P-10
3 H
 (c
pm
)
 
 
Fig 26. Tagged oligosaccharides are substrates of KfiA and pmHS2.  Panel A shows tagged non-sulfated 
HS hexasaccharide could be generated from tagged disaccharide by treated with by KfiA and pmHS2 for 
four cycles.  Panel B shows gel filtration column separation of resultant tagged hexasaccharide 23.  
Arrows indicate the elution positions of oligosaccharide standards: (1) hexa-, (2) tetra-, and (3) di-
saccharides. 
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Fig 27. Structural characterization of hexasaccharide 23.  Panel A shows the MS spectrum of 
nonradioactive hexasaccharide 23.  The MS analysis is conducted by ESI-MS in negative mode.  Panel B 
shows MS/MS of hexasaccharide 23.  The fragmentation pattern is depicted on the bottom.  The product 
ions in MS/MS data were labeled according to the Domon-Costello nomenclature. 
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 Susceptibilities of UDP-GlcNTFA as the donor to KfiA 
To demonstrate the reactivity of the unnatural monosaccharide donor UDP-GlcNTFA 
to glycosyltransferase modification, tagged tetrasaccharide 21 was prepared using the same 
route as described above and subjected to the modification of KfiA by using UDP-GlcNTFA. 
Indeed, KfiA efficiently transfered the GlcNTFA group to the tagged tetrasaccharide 21, the 
resulting tagged pentasaccharide 24 were purified by a fluorous column.  MS analysis of 
pentasacchride 24 revealed the molecular weight to be 1262.0 Da identical to the calculated 
molecular weight of 1262.0 Da.  MS/MS analysis confirmed the position of the GlcNTFA 
residues from the two characteristic daughter ions, Y3 (m/z, 827.4) and C3 (m/z, 653.3), 
products of the cleavage of internal glycosidic linkages (Figure 28).  This demonstrated that 
UDP-GlcNTFA could serve as a good substrate for KfiA.  Tagged disaccharide was also 
subjected to the modification of KfiA in the presence of UDP-GlcNTFA.  Although the 
disaccharide can accept GlcNTFA, the effiency is only 30% compare to UDP-GlcNAc. 
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Fig 28. Structural characterization of pentasaccharide 24.  Panel A shows the synthesis of pentasaccharide 
24.  Panel B shows the MS spectrum of 24.  The MS analysis is conducted by ESI-MS in negative mode. 
Panel C shows the MS/MS analysis of 24.  The fragmentation pattern is depicted on the bottom.  The 
product ions in MS/MS data were labeled according to the Domon-Costello nomenclature.  Rf is the 
fluorous tag. 
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 Section 4. Preparation of N-sulfo hexasaccharide 
Selective de-N-trifluoroacetylation of tagged hexasaccharide  
To demonstrate the GlcNTFA group could be selective de-N-trifluoroacetylated. 
Tagged pentasaccharide 24 was first extended to hexasaccharide 25 using PmHS2 and UDP-
GlcUA as substrate (Figure 29A).  This demonstrated that GlcNTFA could also serve as a 
good acceptor for PmHS2.  It’s known the GlcNTFA unit is highly susceptible to a mild base 
deacetylation (152).  The hexasaccharide 25 was treated with CH3OH, H2O and (C2H5)3N 
(v/v/v = 2:2:1) to remove the –COCF3 group to yield GlcNH2 unit with nearly 100% 
efficiency as described in Chapter II.  The samples were then dried and reconstituted in H2O 
to recover de-N-trifluoroacetylated hexasaccharide 26.  MS analysis revealed a molecular 
weight of 1437.7 Da and 1342.2 Da for hexasaccharide 25, and 26 respectively, very close to 
the calculated molecular weight 1438.1 Da and 1342.1 Da, respectively (Figure 29).  This 
study clearly demonstrated that the GlcNTFA group could be selectively de-N-
trifluoroacetylated while GlcNAc group remains intacted. 
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Fig 29. Structural characterization of hexasaccharide 25 and 26.  Panel A shows the MS spectrum of 
hexasaccharide 25.  The MS analysis is conducted by ESI-MS in negative mode.  Panel B shows the MS 
spectrum of de-N-trifluoroacetylated hexasaccharide 26.  The MS analysis is conducted by ESI-MS in 
negative mode.  Rf is the fluorous tag. 
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 Preparation of N-sulfo tagged hexasaccharide 
To preprare N-sulfated hexasaccahride 27, the de-N-trifluoroacetylated 
hexasaccharide 26 was modified by NST and purified as described in Chapter II.  
Hexasaccharide 27 was resolved as a symmetric peak by HPLC using a C18 column (Figure 
30A).  MS analysis revealed a molecular weight of 1422.2 Da in close agreement to the 
calculated mass of 1422.1 Da.  The structure of N-sulfo hexasaccharide 27 was characterized 
by MS/MS.  The product ions in MS/MS data were labeled according to the classic Domon-
Costello nomenclature.  MS/MS analysis confirmed the position of the GlcNS residues from 
the two characteristic daughter ions, Y3 (m/z, 827.4) and B3 (m/z, 592.4), products of the 
cleavage of internal glycosidic linkage (Figure 30C).  This study demonstrated that the de-N-
trifluoroacetylated oligosaccharide could be modified by NST.  About 300 μg hexasaccharide 
27 with about 40 % yield starting from tagged disaccharide 7 were generated, sufficient 
enough for further studies. 
 
Optimization of mass spectrometry  
Oligosaccharides carrying sulfo groups are notorious for ionization, resulting 
extremely low sensitivity.  In order to search for optimal condition for sulfated 
oligosaccharides, two oligosaccharide standards, including Arixtra (GSK) and heparin 
disaccharide ΔUA-GlcNS6S 28 (Sigma-Aldrich), were applied to optimize the MS condition.  
It was found that lower temperature and higher voltage is able to increase ionization ability 
while desulfation remains low.  Further, samples dissolved in 70% ACN and 10M 
imidazole enhanced the sensitivity.  Therefore, the optimal condition for sulfated samples 
were found to be in negative ionization mode with the electrospray source set to 3000 V and 
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 200 C. Arixtra could be detected at the concentration as low as 10 μM while the 
disaccharide 28 could be detected at the concentration as low as 0.5 μM.  Such difference 
could be due to the fact that Arixtra carried more sulfo groups and intrinsically difficult to be 
ionized.  The optimization was critical for subsequent study for characterizing N-sulfo and O-
sulfo oligosaccharides. 
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Fig 30. Structural characterization of N-sulfated hexasaccharide 27.  Panel A shows the HPLC 
chromatogram of hexasaccharide 27 using a C18 column under reverse phase condition.  Panel B shows the 
MS spectrum of 27.  The MS analysis is conducted by ESI-MS in negative mode.  Panel C shows MS/MS 
of 27 (precursor ion selection at m/z 473.3).  The fragmentation pattern is depicted on the bottom.  The 
product ions in MS/MS data were labeled according to the Domon-Costello nomenclature.  Rf is the 
fluorous tag. 
 85
 Section 5. Preparation of N-sulfo octasaccharide library 
Preparation of HS octasaccharide library 
Encouraged by the results from hexasaccharide, an octasaccharide library differing in 
the numbers and positions of N-sulfo and N-acetyl substituted glucosamine residues was 
prepared.  The synthesis was started with the same fluorous-tagged disaccharide GlcUA-
AnMan-Rf (7).  The size of oligosaccharide backbone was controlled by the number of KfiA 
and PmHS2 modifications.  FluoroFlash column was used to purify the products from 
unreacted UDP-monosaccharides and enzymes.  The position of N-sulfo and N-acetyl 
substituted glucosamine residues was controlled by selecting UDP-GlcNTFA or UDP-
GlcNAc as donor.  After the backbones were built up, the oligosacchrides were selective de-
N-trifluoroacetylated and purified by RP-HPLC.  The de-N-trifluoroacetylated 
octasaccharides were then N-sulfated by NST (Figure 31).  The pure N-sulfated 
octasaccharides could be prepared in only eight steps starting from the tagged disaccharide 7. 
100 μg scale of octasaccharide 5 could be generated. The octasaccharide library was further 
characterized by MS and MS/MS.  
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Fig 31.  Scheme for the synthesis of octasaccharide library 3-6.  The synthesis was begun with GlcUA-
AnMan-Rf.  The product was then elongated to the octasaccharides.  Either GlcNCOCF3 or GlcNAc 
residue will be incorporated into the octasaccharide by KfiA according to target compound.  The -COCF3 
group was selectively removed to yield the GlcNH2 unit and was then N-sulfated by NST.  
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 Characterization of N-sulfo octasaccharide library 
Octasaccharide 3 & 4 (single GlcNS at different positions) and octasaccharide 5 (two 
GlcNS residues) and 6 (no GlcNS), were purified by RP-HPLC and characterized by MS and 
MS/MS.  For example, octasaccharide 3 and 4 has same molecular weight as revealed by MS, 
however, they showed significant different MS/MS pattern.  MS/MS analysis confirmed the 
position of the GlcNS residues in 3 from the two characteristic daughter ions, Y52- (m/z, 
621.9) and B3 (m/z, 554.4), products of the cleavage of an internal glycosidic linkage (Figure 
32) while MS/MS analysis confirmed the position of the GlcNS residues in 4 from the two 
characteristic daughter ions, Y5 (m/z, 1206.6) and B3 (m/z, 592.2), products of the cleavage of 
an internal glycosidic linkage (Figure 33).  Furthermore, octasaccharide 5 was resolved as a 
symmetric peak by HPLC using a C18 column (Figure 34A).  ESI-MS analysis revealed its 
molecular weight to be 1839.6 Da in close agreement to the calculated mass of 1839.5 Da 
(Figure 34B).  MS/MS analysis confirmed the position of the GlcNS residues in 5 (Figure 
34C) from the two characteristic daughter ions, Y5 (m/z, 1244.5) and B3 (m/z, 592.3), 
products of the cleavage of an internal glycosidic linkage.  Octasaccharide 6 has no GlcNS 
with repeating disaccharide structure; therefore, the MS/MS study was not performed (Figure 
35).  The results from these studies demonstrated that we were able to synthesize 
oligosaccharides having defined N-sulfation positions. 
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Fig 32.  Structural characterization of octasaccharide 3.  Panel A shows the HPLC chromatogram of 
octasaccharide 3 using a C18 column under reverse phase condition.  Panel B shows the mass spectrometry 
spectrum of octasaccharide 3.  The MS analysis is conducted by ESI-MS in negative mode.  MS analysis 
revealed a molecular weight of 1801.8 Da in close agreement to the calculated mass of 1801.5 Da.  Panel 
C shows MS/MS of octasaccharide 3.  MS/MS analysis (precursor ion selection at m/z 449.5) confirmed 
the position of the GlcNS residues in 3 from the two characteristic daughter ions, Y52- (m/z, 621.9) and B3 
(m/z, 554.4), products of the cleavage of an internal glycosidic linkage.  The fragmentation pattern is 
depicted in the top.  The product ions in MS/MS data were labeled according to the Domon-Costello 
nomenclature.  Rf is the fluorous tag. 
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Fig 33.  Structural characterization of octasaccharide 4.  Panel A shows the HPLC chromatogram of 
octasaccharide 4 using a C18 column under reverse phase condition.  Panel B shows the mass spectrometry 
spectrum of octasaccharide 4.  The MS analysis is conducted by ESI-MS in negative mode.  MS analysis 
revealed a molecular weight of 1802.1 Da in close agreement to the calculated mass of 1801.5 Da.  Panel 
C shows MS/MS of octasaccharide 4.  MS/MS analysis (precursor ion selection at m/z 449.5) confirmed 
the position of the GlcNS residues in 4 from the two characteristic daughter ions, Y5 (m/z, 1206.6) and B3 
(m/z, 592.2), products of the cleavage of an internal glycosidic linkage.  The fragmentation pattern is 
depicted in the top.  The product ions in MS/MS data were labeled according to the Domon-Costello 
nomenclature.  Rf is the fluorous tag. 
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Fig 34. Structural characterization of octasaccharide 5.  Panel A shows the HPLC chromatogram of 
octasaccharide 5 using a C18 column under reverse phase condition.  Panel B shows the MS spectrum of 
octasaccharide 5.  The MS analysis is conducted by ESI-MS in negative mode.  MS analysis revealed its 
molecular weight to be 1839.6 Da in close agreement to the calculated mass of 1839.5 Da.  Panel C shows 
MS/MS of octasaccharide 5 (precursor ion selection at m/z 459.1).  MS/MS analysis confirmed the 
position of the GlcNS residues in 5 from the two characteristic daughter ions, Y5 (m/z, 1244.5) and B3 (m/z, 
592.3), products of the cleavage of an internal glycosidic linkage.  The fragmentation pattern is depicted in 
the top.  The product ions in MS/MS data were labeled according to the Domon-Costello nomenclature.  
Rf is the fluorous tag. 
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Fig 35. Structural characterization of octasaccharide 6.  The MS analysis is conducted by ESI-MS in 
negative mode.  MS analysis revealed a molecular weight of 1763.8 for octasaccharide 6 in close 
agreement to the calculated mass of 1763.4 Da.  Rf is the fluorous tag. 
 
Section 6. Conclusion 
The current study demonstrates the feasibility of a total synthesis of structurally 
defined HS oligosaccharides using a chemoenzymatic approach.  This method is capable of 
synthesizing oligosaccharides with different N-sulfation patterns and structures by 
transferring UDP-sugars onto an easily prepared disaccharide acceptor.  A key advance 
involves the utilization of an unnatural UDP-donor that allows the controlled placement of 
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GlcNS and GlcNAc residues throughout the oligosaccharide backbone. The GlcNS/GlcNAc 
patterning likely controls the subsequent positioning of O-sulfo groups. 
One challenge in using oligosaccharides for the substrate specificity study is to purify 
the products from the reaction mixture.  The application of a fluorous tag at the reducing end 
of the substrate allows us to obtain salt-free oligosaccharides in much fewer steps with very 
high efficiency.  For example, we can prepare about 100 μg pure N-sulfated octasaccharide 5 
in only eight steps starting from the tagged disaccharide 7 with about 30% yield.  The 
purified oligosaccharides are also amendable for the analysis by ESI-MS and MS/MS as 
demonstrated in this project. 
Chapter IV SYNTHESIS OF 6-O-SULFO OLIGOSACCHARIDES 
 
Section 1. Introduction 
In Chapter III, an octasaccharide library with different N-sulfation patterns was 
synsthesized.  However, whether this method is capable of further converting to 
oligosaccharides with O-sulfo group is unclear.  In this chapter, the N-sulfo oligosaccharides 
are modified with 6OSTs to prepare different oligosaccharides with defined 6-O-sulfation 
patterns. 
 
Section 2. N-sulfo-6-O-sulfo oligosaccharides 
Preparation of N-sulfo-6-O-sulfo hexasaccharides 
The synthesis of N-sulfo-6-O-sulfo hexasacchride was carried out by modifying N-
sulfo hexasaccharide 27 with 6OSTs using 35S-labeled PAPS as a sulfo donor, permitting to 
introduce 35S-label for purification and characterization.  The 6-O-sulfo hexasaccharide 29, 
30 were prepared by controlling the amount of PAPS.  Hexasaccharide 29 carrying only one 
6-O-sulfo group was successfully prepared under the condition that insufficient amount of 
PAPS was added.  In contrast, if excess amount of PAPS was added, two 6-O-sulfo groups 
were introduced to form hexsaccahride 30 (Figure 36). The tagged 6-O-sulfo hexasaccharides
 
 were initially purified by a C18 column under reverse phase HPLC (RP-HPLC) conditions. 
Hexasaccharide was then analysis by a DEAE-HPLC column. Both 29 and 30 was resolved 
as a symmetric peak by DEAE-HPLC.  However, 29 and 30 exhibit different retention times, 
suggesting two hexasacchrides have different amount of 6-O-sulfo groups.  Since 30 was 
eluted later than 29, 6-O-sulfo hexasaccharide 29 likely has only one 6-O-sulfo group while 
6-O-sulfo hexasaccharide 30 has two 6-O-sulfo groups (Figure 37). 
 
 
 
Fig 36. Preparation of N-sulfo-6-O-sulfo hexasaccharide 29 and 30.  In preparation of 29, insufficient 
amount PAPS was applied while excess amount of PAPS was applied in preparation of 30.  The 6-O-
[35S]sulfo group was colored in red to indicate the site of radioactive sulfate.  Rf is the fluorous tag. 
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Fig 37. HPLC analysis of 6-O-sulfo hexasaccharide 29 and 30.  Panel A shows the HPLC chromatogram 
of 6-O-[35S]sulfo-labeled hexasaccharide 29 using a DEAE-HPLC column.  Panel B shows the HPLC 
chromatogram of 6-O-[35S]sulfo-labeled hexasaccharide 30 using a DEAE-HPLC column.  The HPLC 
chromatogram shows 29 and 30 have different retention time, hexasaccharide 29 eluted at 35 min while 
hexasaccharide 30 eluted at 48 min.  These results suggested 29 and 30 have different amount of 6-O-sulfo 
groups.  
 
Characterization of N-sulfo-6-O-sulfo hexasaccharides 
Hexasaccharide 29 was analyzed by disaccharide analysis to elucidate the structure. 
The reaction mixture contained approximately 50,000 cpm 29, 50 mM NaH2PO4, pH 7.0, 30 
μL Hep I, 10 μL Hep II and 10 μL Hep III proteins in a total volume of 250 μL.  The reaction 
was incubated at 37 °C for 2 days, another dose of Hep I, II and III was added after initial 24 
hours incubation.  The disaccharide sample was then analyzed by using a C18 column under 
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 RPIP-HPLC conditions, which was resolved as a single symmetric peak by HPLC at 18 
minutes, indicating a ΔUA-GlcNAc6S group, but not ΔUA-GlcNS6S (Figure 38).  Therefore, 
the structure of 29 was GlcUA-GlcNS-GlcUA-GlcNAc6S-GlcUA-AnMan-Rf. 
Since hexasaccharide 30 has two 6-O-sulfo groups, the structure of 30 should be 
GlcUA-GlcNS6S-GlcUA-GlcNAc6S-GlcUA-Anman-Rf.  The hexasaccharide 30 was 
resynthesized by the same procedure as described previously using 80 M ublabeled PAPS 
as sulfo donor.  The sample was analyzed by MS and MS/MS. MS analysis revealed the 
molecular weight to be 1582.7 Da in close agreement to the calculated mass of 1582.3 Da, 
confirming the structure of the hexasaccharide 30.  The structure of N-sulfo-6-O-sulfo 
hexsaccahride was further proved by MS/MS. MS/MS analysis confirmed the position of the 
GlcNS6S residues from the two characteristic daughter ions, Y3 (m/z, 907.4) and [B3-SO3] 
(m/z, 592.3), products of the cleavage of internal glycosidic linkage (Figure 39).  These 
studies demonstrated the tagged hexasaccharide with defined 6-O-sulfation patterns could be 
synthesized by taking advantage of 6OSTs substrate specificity.  
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Fig 38. Determination of the structure for 6-O-sulfo hexasaccharide 29.  Panel A shows the HPLC 
chromatogram of the disaccharide analysis of 29 using a C18 column under RPIP-HPLC conditions.  Only 
a single 35S-labeled disaccharide (ΔUA-GlcNAc6S) was observed, suggesting that 29 is GlcUA-GlcNS-
GlcUA-GlcNAc6S-GlcUA-Anman-Rf.  Panel B shows the reaction involved in the disaccharide analysis 
of 29.  The 6-O-[35S]sulfo group was colored in red to indicate the site of radioactive sulfate.  The identitiy 
of 35S-labeled disaccharide was confirmed by coeluting with authetic disaccharide standard.  Rf is the 
fluorous tag. 
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Fig 39. Structural characterization of hexasaccharide 30.  Panel A shows the HPLC chromatogram of 
octasaccharide 3 using a C18 column under reverse phase condition.  Panel B shows the MS spectrum of 
hexasaccharide 30.  The MS analysis is conducted by ESI-MS in negative mode.  Molecular ions are 
labeled as 1 through 5, where 1 is 374.9 [M-SO3-4H]4- ; 2 is 394.6 [M-4H]4-; 3 is 499.9 [M-SO3-3H]3-; 4 is 
507.2 [M+Na-SO3-4H]3-; 5 is 533.7 [M+Na-4H]3-.  Panel C shows MS/MS of hexasaccharide 30.  The 
fragmentation pattern is depicted on the bottom.  The product ions in MS/MS data were labeled according 
to the Domon-Costello nomenclature.  Rf is the fluorous tag. 
 
Preparation of N-sulfo-6-O-sulfo octasaccharide 
The 6-O-sulfo octasaccharide 31 was prepared by incubating 6OST1 and 6OST3 with 
N-sulfo octasaccharide substrate 5.  MS analysis revealed a molecular weight of 2080.7 Da in 
close agreement to the calculated mass of 2079.7 Da.  The detailed structure of 
octasaccharide 31 was analyzed by MS/MS.  MS/MS analysis confirmed the position of the 
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 GlcNS6S residues from the two characteristic daughter ions, [Y6–SO3]4- (m/z, 374.7) and B42-
(m/z, 497.4), products of the cleavage of internal glycosidic linkage (Figure 40).  These 
studies demonstrated different size of tagged oligosaccharide could be fully O-sulfated by 
6OSTs. 
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Fig 40. Structural characterization of octasaccharide 31.  Panel A shows the HPLC chromatogram of 
octasaccharide 3 using a C18 column under reverse phase condition.  Panel B shows the MS spectrum of 
octasaccharide 31.  The MS analysis is conducted by ESI-MS in negative mode.  Molecular ions are 
labeled as 1 through 6, where 1 is 415.6 [M-5H]5- ; 2 is 459.1 [M-3SO3-4H]4-; 3 is 479.7 [M-2SO3-4H]4-; 4 
is 500.0 [M-SO3-4H]4-; 5 is 509.6 [M+2Na-SO3-6H]4-; 6 is 523.4 [M+Na-5H]4-.  Panel C shows MS/MS of 
octasaccharide 31.  The fragmentation pattern is depicted on the bottom.  The product ions in MS/MS data 
were labeled according to the Domon-Costello nomenclature.  Rf is the fluorous tag. 
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 Fluorous tag does not bind with AT  
The fluorous tagged oligosaccharide library could be used for microarray for probing 
the structural selectivity of HS for interacting wth proteins, especially with AT.  However, it 
is possible that nonspecific interaction between protein and fluorous tag exist.  Therefore, N-
sulfo-6-O-[35S]sulfo hexasaccharide 30 was applied for AT-binding assay.  Since 
hexasaccharide 30 has no 3-O-sulfation, it should not bind to AT. A nonasaccharide 32 from 
Dr. Yongmei Xu with known AT-binding activity was used as a positive control (Figure 41) 
while [35S] labeled PAPS worked as a negative control. The results were summarized in 
Table 3.  The result indicates there is no binding affinity of N-sulfo-6-O-[35S]sulfo 
hexasaccharide 30 to the AT, suggesting the fluorous tag is not able to increase the binding 
of tagged oligosaccharide to AT through nonspecific interactions.  However, it’s not clear 
whether the tag will prohibit the AT-binding. 
 
 
Fig 41. Structure of nonasaccharide 32. Nonasaccharide 32 is received from Dr. Yongmei Xu with known 
AT-binding activity. 
 
Table 3. AT binding assay for 30, 32 and [35S] PAPS. 
 Amount of samples (cpm) Binding affinity (%) 
Nonasaccharide 32 4820 35% 
hexasaccharide 30 3820 < 1% 
[35S] PAPS 7690 < 1% 
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Section 3. Conclusion 
In this study, two different hexasaccharides 29 and 30 have been successfully 
prepared.  The HPLC indicating that hexasacchride 29 only has one 6-O-sulfo group, 
however, it could be GlcNAc6S or GlcNS6S or mixture of both. To our surprise, 
disaccharide analysis of 29 only gave ΔUA-GlcNAc6S, indicating 29 is GlcUA-GlcNS-
GlcUA-GlcNAc6S-GlcUA-Anman-Rf.  This could be due to the reason that the GlcNAc 
residue is in the middle of hexasaccharide, favoring the substrate recognition. Therefore, 
6OSTs prefer to modify GlcNAc residue first if the amount of PAPS is not sufficient.  If 
excess amount of PAPS applied, the tagged hexasaccharide could be fully O-sulfated by 
6OSTs to generate hexasaccharide 30.  These studies demonstrated that we could prepare 
oligosaccharide with different 6-O-sulfation patterns.  The synthesis of octasaccharide 31 
demonstrated tagged N-sulfo oligosaccharide of different size could be fully O-sulfated by 
6OSTs. 
The success of this project can help to develop a reliable protocol to position the 
remaining modifications, such 2-O- and 3-O-sulfation as well as IdoUA.  For example, we 
can investigate the substrate specificities of these enzymes in greater details using a series of 
structurally defined N-sulfo oligosaccharides. The studies from 6OST modified 
oligosaccharide demonstrate the potential of this approach. 
While this method is fully capable of synthesizing large libraries of diverse HS 
oligosaccharide structures, it is currently limited by the time and effort required for the full 
structural characterization of the resulting oligosaccharide products.  More studies will be 
performed to generate structurally defined oligosaccharides with various biological functions. 
Chapter V SYNTHESIS OF AT-BINDING OLIGOSACCHARIDES 
 
Section 1. Introduction 
In this chapter, in collaboration with Dr. Yongmei Xu, a reliable protocol has been 
developed to position the remaining modifications, such as 3-O- and 6-O-sulfation.  Here, the 
introduction of O-sulfo groups was completed using O-sulfotransferases.  Deca, undeca and 
dodecasaccharides with N-sulfo groups was synthesized, as the actions of O-sulfotransferases 
require the presence of GlcNS residues. The synthesis began with the disaccharide acceptor 1.  
The disaccharide will be extended to a large oligosaccharide with N-sulfation.  As mentioned 
previously, GlcNCOCF3 residue will be incorporated into the oligosaccharides by KfiA.  The 
-COCF3 group will selectively be removed by mild-base and is then N-sulfated by NST.  
Furthermore, we will modify the N-sulfated oligosaccharides by 6OSTs and 3OSTs to design 
a structurally defined dodecasaccharide with AT-binding activity (Figure 42).   
It’s known that the AT-binding correlates to HS anticoagulant activity.  Our lab 
previously demonstrated that an AT-binding HS does not require the presence of IdoUA or 
IdoUA2S residues, which simplified the synthesis of AT-binding HS (123).  However, the 
minimum length and the precise structure of this novel AT-binding domain were not known.  
The purified oligosaccharides have been examined for their AT binding activity. 
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Fig 42.  Scheme for the synthesis of oligosaccharides.  The synthesis is begun with a disaccharide 1 
(GlcUA-AnMan).  The product was then elongated to the decasaccharide (8), undecasaccharide (9), 
dodecasaccharide (10) as described. GlcNCOCF3 residue will be incorporated into the oligosaccharides by 
KfiA.  The -COCF3 group has selectively been removed by mild-base to yield the GlcNH2 unit.  The 
resultant GlcNH2 unit was then N-sulfated by NST to prepare decasaccharide (11), undecasaccharide (12), 
dodecasaccharide (13).  The synthesized N-sulfo decasaccharide (11) and dodecasaccharide (13) were 
modified by 6OST1 and 6OST3 to prepare N-sulfo 6-O-sulfo decasaccharide (14) and dodecasaccharide 
(15), respectively and further modified by 3OST1 and 3OST5 to prepare 3-O-sulfo decasaccharide (16) 
and dodecasaccharide (17), respectively.  
 
Section 2. Preparation of AT-Binding oligosaccharides 
Preparation of backbone oligosaccharides 
Disaccharide acceptor 1 was extended to backbone decasaccharide 8, 
undecasaccharide 9 and dodecasaccharide 10 respectively using the UDP-GlcNTFA and 
UDP-GlcUA donors.  The structures of the backbone oligosaccharides were confirmed by 
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 LC-MS (Table 4).  In eight enzymatic steps at the milligram-scale, a disaccharide was 
converted to a decasaccharide.  Further extension to undeca- and dodecasaccharide was also 
highly effective.  While some unexpected partial detrifluoroacetylation occurred for those 
backbones, it did not affect the subsequent synthesis to prepare N-sulfated oligosaccharides. 
 
Table 4.  List of the synthesized oligosaccharide backbones 
 
Amount (mg) Molecular formula Molecular weight (Da) a Oligosaccharides   Calculated Determined 
Decasaccharide 8 4.5 C64F6H94N4O53 1881.4 1882.2 
Undecasaccharide 9b 2.1 C72F9H104N5O58 2138.6 2138.0 
Dodecasaccharide 10b 0.9 C78 F9H112N5O64 2314.7 2314.8 
 
a. Oligosaccharides 8-9 lost two trifluoroacetyl groups during the purification.  The calculated 
molecular mass was based on the lost of two trifluoroacetyl groups. 
b. Only half of the decasaccharide 8 was converted to the undecasaccharide 9.  Similarly, only half 
of the undecasaccharide 9 was converted to the dodecasaccharide 10.   
 
Preparation of N-sulfo oligosaccharides 
Conversion of the GlcNTFA in decasaccharide 8, undecasaccharide 9 and 
dodecasaccharide 10 to GlcNH2 were through de-trifluoroacetylation as previously described, 
the samples were further treated with NST using [35S]PAPS afforded N-[35S]sulfated 
products.  The oligosaccharides showed predominantly a single 35S-peak on high resolution 
DEAE-HPLC chromatography, suggesting the products were homogeneous (Figure 43A, C 
and E).  The N-sulfo oligosaccharides (11 to 13) were resynthesized using NST and 
unlabeled PAPS and purified by DEAE-HPLC.  The results of ESI-MS analysis of the 
unlabeled oligosaccharides (Figure 43B, D and F) confirmed that all three compounds are 
fully N-sulfated with the structures shown in Figure 42.  
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Fig 43.  Structural characterization of N-sulfo oligosaccharides 11-13.  Panel A, C, E shows the HPLC 
chromatogram of decasaccharide 11, undecasaccharide 12 and dodecasaccharide 13 respectively using a 
DEAE-column.  Panel B, D, F shows the MS spectrum of decasaccharide 11, undecasaccharide 12 and 
dodecasaccharide 13 respectively.  The MS analysis is conducted by ESI-MS in negative mode.  MS 
analysis revealed that decasaccharide 11, undecasaccharide 12 and dodecasaccharide 13 had molecular 
weights of 2009.3 Da, 2250.7 Da and 2427.4 Da, respectively, consistent with a calculated mass of 2009.7 
Da, 2250.9 Da and 2427.0 Da. 
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 Preparation of N-sulfo-6-O-sulfo deca and dodecasaccharide 
Next, we introduced 6-O-sulfo groups using a mixture of 6OST1 and 6OST3 
affording the N-sulfo-6-O-sulfo decasaccharide 14 and N-sulfo-6-O-sulfo-dodecasaccharide 
15 (Figure 44).  DEAE-HPLC analysis of the 35S-labeled oligosaccharide displayed a 
symmetric 35S-peak, suggesting that the 6-O-sulfated product was homogeneous (Figure 44A 
and C).  Both nonradioactively labeled decasaccharide 14 and dodecasaccharide 15 were 
resynthesized using unlabeled PAPS, purified by DEAE-HPLC and subjected to MS analysis.  
Data of ESI-MS analysis revealed that decasaccharide 14 and dodecasaccharide 15 (Figure 
44B and D) had molecular weights of 2329.9 Da and 2828.1 Da, respectively, consistent with 
a calculated mass of 2329.9 Da and 2827.3 Da for a decasaccharide with eight sulfo groups 
and a dodecasaccharide with ten sulfo groups.   
The disaccharide analysis of decasaccharide 14 and dodecasaccharide 15 carrying 
site-specific [35S]sulfo groups also confirmed their structures.  Here, the [35S]sulfo groups 
were selectively introduced at the N-[35S]sulfation sites of the oligosaccharides 14 and 15.  
The oligosaccharides were then degraded to the disaccharides using heparin lyases followed 
by the analysis using RPIP-HPLC.  We observed two types of disaccharides, namely GlcUA-
[N-35S]GlcNS6S and UA-[N-35S]GlcNS6S.  Furthermore, the molar ratio of UA-GlcNS6S 
and GlcUA-GlcNS6S was 2.9 and 3.5 for decasaccharide 14 and dodecasaccharide 15, 
respectively.  It should be noted that the theoretical value of the ratio of two disaccharides is 
3 for the decasaccharide 14 and 4 for the dodecasaccharide 15 respectively (Table 5). 
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 Table 5.  Summary of disaccharide analysis of decasaccharide 14 and dodecasaccharide 15  
 
Oligosaccharides Method for 
degradations 
Composition 2 Measured molar ratio  
N-[35S]sulfo-6-O-
sulfo decasaccharide 
141 
Heparin lyase 
I, II and III 
GlcUA-GlcNS6S 
and UA-GlcNS6S 
1 : 2.9 (1:3)3 
N-[35S]sulfo-6-O-
sulfo 
dodecasaccharide 151 
Heparin lyase 
I, II and III 
GlcUA-GlcNS6S 
and UA-GlcNS6S 
1 : 3.5 (1: 4)3 
 
1. The decasaccharide 14 was prepared by incubating the N-[35S]sulfo decasaccharide 11 with 6OST1 
and 6OST3.  To this end, all the radioactive [35S]sulfate was at the N-sulfo group.  Likewise, the 
dodecasaccharide 15 was prepared by incubating the N-[35S]sulfo dodecasaccharide 13 with 6OST1 
and 6OST3. 
2. Disaccharide analysis was carried out using reverse phase ion-pairing HPLC (RPIP-HPLC). 
3. The numbers presented in parenthesis indicate the calculated values based on the proposed structures. 
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Fig 44.  Structural characterization of decasaccharide 14 and dodecasaccharide 15.  Panel A shows the 
HPLC chromatogram of 35S-labeled decasaccharide 14 using a DEAE-HPLC column.  Panel B shows the 
MS spectrum of decasaccharide 14.  The MS analysis is conducted by ESI-MS in negative mode.  The 
decasaccharide was purified by DEAE-HPLC, the purified decasaccharide was dialyzed against 20 mM 
ammonium acetate prior to the MS analysis.  Additional molecular ions are labeled as 1 through 5, where 
1 is 748.9 [M-SO3-3H]3- ; 2 is 561.5 [M-SO3-4H]4-; 3 is 541.4 [M-2SO3-4H]4-; 4 is 521.8 [M-3SO3-4H]4-; 
5 is 501.5 [M-4SO3-4H]4-.  Panel C shows the HPLC chromatogram of 35S-labeled dodecasaccharide 15 
using a DEAE-HPLC column.  Panel D shows the MS spectrum of dodecasaccharide 15.  The MS analysis 
is conducted by ESI-MS in negative mode.  The decasaccharide was purified by DEAE-HPLC, the 
purified decasaccharide was dialyzed against 20 mM ammonium acetate prior to the MS analysis. 
Additional molecular ions are labeled as 6 through 10, where 6 is 686.1 [M-SO3-4H]4-; 7 is 666.1 [M-
2SO3-4H]4-; 8 is 646.0 [M-3SO3-4H]4-; 9 is 549.0 [M-SO3-5H]5-; 10 is 501.0 [M-4SO3-5H]5-. 
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 Preparation of oligosaccharides binding to AT 
Next, we prepared oligosaccharides capable of binding to antithrombin (AT).  The 
AT-binding correlates to HS anticoagulant activity.  We previously demonstrated that an AT-
binding HS does not require the presence of IdoUA or 2-O-sulfo-iduronic acid residues, 
which simplified the synthesis of AT-binding HS.  However, the minimum length and the 
precise structure of this novel AT-binding domain were not known.  We hypothesized that 
the preparation of decasaccharide 16 and dodecasaccharide 17 should provide insights on the 
structural requirement for this AT-binding site.  Incubation of oligosaccharides 14 and 15 
with 3OST1 and 3OST5 in the presence of [35S]PAPS afforded 35S-labeled decasaccharide 16 
and dodecasaccharide 17.  The 35S-labeled decasaccharide 16 and dodecasaccharide 17 were 
purified by DEAE-HPLC.  Using a site-specific [35S]sulfo-labeled technique followed by 
disaccharide analysis (Figure 45-50), we proved the structure of  decasaccharide 16 to be 
(GlcUA-GlcNS3S6S)4-GlcUA-AnMan (as shown in Figure 45) and dodecasaccharide 17 to 
be (GlcUA-GlcNS3S6S)5-GlcUA-AnMan (as shown in Figure 48). 
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Fig 45. Preparation of 3-O-sulfo decasaccharide 16.  Panel A shows the HPLC chromatogram of 6-O-
[35S]sulfo-labeled decasaccharide 16 using a DEAE-HPLC column.  The decasaccharide was prepared by 
incubating decasaccharide 14 with 3OST1 and 3OST5 as depicted in Panel B.  Two major products, 
designated as Peak I and Peak II, were observed.  Both components were purified and subjected to 
disaccharide analysis.  The 6-O-[35S]sulfo group was colored in red to indicate the site of radioactive 
sulfate. 
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Fig 46. Determination of the structures of peak I for decasaccharide 16.  Panel A shows the HPLC 
chromatogram of the disaccharide analysis of Peak I using a C18 column under RPIP-HPLC conditions.  
Two 35S-labeled disaccharides, including GlcUA-AnMan6S and GlcUA-AnMan3S6S, were observed. The 
data suggest that Peak I is a partially 3-O-sulfated decasaccharide.  Because the molar ratio of those two 
disaccharides was 1: 3.4, we concluded that Peak I carries only three 3-O-sulfo groups.  Panel B shows the 
reaction involved in the disaccharide analysis of Peak I.  The 6-O-[35S]sulfo group was colored in red to 
indicate the site of radioactive sulfate.  To improve the clarity, nonradioactively labeled disaccharides 
resulted from nitrous acid degradation was not indicated. 
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Fig 47. Determination of the structures of peak II for decasaccharide 16.  Panel A shows the HPLC 
chromatogram of the disaccharide analysis of Peak II using a C18 column under RPIP-HPLC conditions.  
Only a single 35S-labeled disaccharide (GlcUA-AnMan3S6S) was observed, suggesting that Peak II is a 
fully 3-O-sulfo decasaccharide.  Peak II was therefore designated as decasaccharide 16 for the 
antithrombin-binding study as described in the text.  Panel B shows the reaction involved in the 
disaccharide analysis of Peak II.  The 6-O-[35S]sulfo group was colored in red to indicate the site of 
radioactive sulfate.  To improve the clarity, nonradioactively labeled disaccharides resulted from nitrous 
acid degradation was not indicated. 
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Fig 48.  Preparation of 3-O-sulfo dodecasaccharide 17.  Panel A shows the HPLC chromatogram of 6-O-
[35S]sulfo-labeled dodecasaccharide 17 using a DEAE-HPLC column.  The dodecasaccharide was 
prepared by incubating dodecasaccharide 15 with 3OST1 and 3OST5 as depicted in Panel B.  Two major 
products, designated as Peak I and Peak II, were observed.  Both components were purified and subjected 
to disaccharide analysis.  We noted that the resolution of Peak I and II was not base-line separation as we 
obtained for the decasaccharide (Figure 45).  The 6-O-[35S]sulfo group was colored in red to indicate the 
site of radioactive sulfate.  
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Fig 49. Determination of the structures of peak I for dodecasaccharide 17.  Panel A shows the HPLC 
chromatogram of the disaccharide analysis of Peak I using a C18 column under RPIP-HPLC conditions.  
Two 35S-labeled disaccharides, including GlcUA-AnMan6S and GlcUA-AnMan3S6S, were observed.  
The data suggest that Peak I is a partially 3-O-sulfated dodecasaccharide.  Because the molar ratio of those 
two disaccharides was 1: 3.7, we concluded that Peak I carries only four 3-O-sulfo groups.  Panel B shows 
the chemical reaction involved in the disaccharide analysis of Peak I.  The 6-O-[35S]sulfo group was 
colored in red to indicate the site of radioactive sulfate.  To improve the clarity, nonradioactively labeled 
disaccharides resulted from nitrous acid degradation was not indicated. 
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Fig 50. Determination of the structures of peak II for dodecasaccharide 17.  Panel A shows the HPLC 
chromatogram of the disaccharide analysis of Peak II using a C18 column under RPIP-HPLC conditions.  
Predominantly a single 35S-labeled disaccharide (GlcUA-AnMan3S6S) with very small amount of GlcUA-
AnMan6S was observed, suggesting that Peak II is a fully 3-O-sulfo dodecasaccharide.  The reason for the 
small amount of GlcUA-AnMan6S was likely due to the contamination of Peak I, provided that the base-
line separation of Peak I and II was not achieved.  Peak II was therefore designated as dodecasaccharide 
17 for the antithrombin-binding study as described in the main text.  Panel B shows the reaction involved 
in the disaccharide analysis of Peak II.  The 6-O-[35S]sulfo group was colored in red to indicate the site of 
radioactive sulfate.  To improve the clarity, nonradioactively labeled disaccharides resulted from nitrous 
acid degradation was not indicated. 
 
The AT-binding affinities 
The AT-binding affinities of oligosaccharides 15, 16 and 17 were determined (Table 
6).  Dodecasaccharide 17 showed a dissociation constant (Kd) of 145 nM, close to that of a 
full length HS polysaccharide (57 nM) (124).  The Kd value measured for decasaccharide 16 
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 was 515 nM, showing considerably weaker binding to AT, clearly demonstrating the size-
dependency for HS binding to AT.  Dodecasaccharide 9, having no 3-O-sulfo groups, 
exhibited a Kd of >100 M.  These results confirmed the critical role of 3-O-sulfo groups for 
AT-binding.  While the dodecasaccharide 17 binds AT with lower affinity than does the 
commercial pentasaccharide drug, Arixtra, improvement of dodecasaccharide binding 
affinity to AT may be possible by modifying its sequence through the appropriate placement 
of GlcNAc residues. 
 
Table 6.  The binding affinity of oligosaccharides to AT 
Substrates Proposed structure Kd(nM) 
16       (GlcUA-GlcNS3S6S)4-GlcUA-AnMan 515 ± 40 
17 (GlcUA-GlcNS3S6S)5-GlcUA-AnMan 145 ± 24 
15 (GlcUA-GlcNS6S)5 -GlcUA-AnMan >100,000 
Arixtra2 GlcNS6S-GlcUA-GlcNS3S6S-IdoUA2S-GlcNS6S-OMe 33 
Recomparin3 Polysaccharide, no defined structure 57 
 
1. The binding affinity of the oligosaccharides to AT was determined using affinity co-
electrophoresis.  
2. The 35S-labeled Arixtra was prepared as described previously.   
3. The binding affinity of Recomparin to AT was taken from our previous publication.  
 
Section 3. Conclusion 
The current study demonstrates the feasibility of a total synthesis of structurally 
defined HS dodecasaccharides with AT-binding activity using a chemoenzymatic approach.  
This method is capable of synthesizing oligosaccharides with different sulfation patterns and 
structures by transferring UDP-sugars onto an easily prepared disaccharide acceptor. 
Advances in analytical methods will be required to expand our synthesis to a greater and 
more structurally complex variety of defined oligosaccharide structures.  This study 
demonstrated the viability of synthesis structurally defined large HS oligosaccharide with 
 117
  118
biological functions.  Synthetic HS oligosaccharides could be employed to interrogate the 
structure and activity relationship in the new field of HS glycomics.  These results also open 
a possibility to prepare novel HS-based anticoagulant drugs as well as other HS-based 
therapeutic agents. 
Chapter VI SOLID PHASE SYNTHESIS OF HS 
 
Section 1. Introduction 
This chapter describes the attempt for enzyme-based synthesis on a solid support.  
The method would provide advantages over solution-phase synthesis: First, the 
oligosaccharide is immobilized; so sample loss during subsequent manipulations is minimal. 
Second, large excesses of reagents could be used to drive reactions to completion.  Third, if a 
cleavable linker is present in the capture molecule, the processed oligosaccharide can be 
released into solution in a small volume for further analysis.  Here, our research effort will 
focused on immobilizing a disaccharide on the solid support and examine the ability of 
glycotransferase KifA and pmHS2 to alternatively incorporate GlcNAc and GlcUA residues, 
from UDP-GlcNAc and UDP-GlcUA to the nonreducing ends of the immobilized 
disaccharide.  
Considering enzymes are large molecules, one must be careful for choosing the 
support for solid-phase synthesis.  For the porous support, the material should have pores 
large enough to accommodate these macromolecules and should be hydrophilic to allow good 
compatibility in water, or the solid support should be rigid therefore the enzyme will not be 
entrapped (168, Figure 51).  Therefore, two different solid supports have been investigated: 
polyethylene glycol-polyacrylamide resin (PEGA) which swells in both organic and aqueous 
solvents and has functional amino groups incorporated in the range of 0.4 mmol g-1; and 
 
 controlled-pore glass (CPG), which comprises rigid particles having pores of size >1400 Å 
and near 60 µmol g-1 incorporated amino groups.  
 
 
 
Fig 51. Solid phase HS oligosaccharide synthesis.  Panel A shows the disaccharide will be immobilized to 
solid phase through a linker or optionally through a spacer molecule.  Panel B shows the glycotransferases 
KfiA and pmHS2 will transfer a GlcNAc or GlcUA moiety to the solid phase to build up HS 
oligosaccharides. 
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 Section 2. Solid phase synthesis 
Preparation of Resins 1 and 2 
Guillaumie and coworkers has reported to successfully immobilize oligosaccharide 
from pectin onto PEGA support via a hydroxylamine or hydrazide terminated group (169). 
Both resins were prepared (Resin 1 and 2) followed this report.  Briefly, to prepare 
hydroxylamine resin 1, reactions were carried out in a 10 mL plastic column equipped with a 
scintered Teflon filter.  Amino PEGA resin (600 mg, wet) was initially washed with DMF (3 
× 1 mL), 10% DIPEA in DMF (3 × 1 mL), and DMF (3 × 1 mL). 1.5 mL DMF containing 
Nµ-Boc-aminooxy acetic acid (Nµ-Boc-Aoa-OH, 20 mg, 0.1 mmol), benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP, 27 mg, 0.1 mmol), 1-
hydroxybenzotriazole (HOBt, 14 mg, 0.1 mmol) and DIPEA (35 µL, 0.2 mmol) was then 
added to the resin.  After the column was shaken at room temperature for overnight, the 
reagents were removed by suction and washed with DMF (3 × 1 mL) and CH2Cl2 (4 × 1 mL).  
A qualitative ninhydrin test was used to monitor the reaction by examining the remaining 
level of primary amino group.  After confirming the occupation of primary amine was 
completed, the removal of Boc groups was accomplished by treatment with 50% TFA in 
CH2Cl2 for 3 hour at room temperature (Figure 52).  The resin was washed with CH2Cl2 (4 × 
1 mL), DMF (3 × 1 mL) and CH2Cl2 (3 × 1 mL) respectively.  A qualitative ninhydrin test 
was used to indicate the reaction was completed. The same procedure was used to prepare 
CPG resin. 
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Fig 52. Preparation of hydroxylamine resin 1. 
 
To prepare the hydrazide-terminated resin 2, reactions were carried out in a 10 mL 
plastic column equipped with a scintered Teflon filter.  Amino PEGA resin (400 mg, wet) 
was initially washed with DMF (3 × 1 mL).  DMF solution (1 mL) containing succinic 
anhydride (20 mg, 0.12 mmol) and O-(benzotriazol-1-yl)-N, N, N', N'-tetramethyluronium 
tetrafluoroborate (TBTU, 40 mg, 0.12 mmol) DIPEA (30 µL, 0.18 mmol) was then added to 
the resin and the column was shaken at room temperature for overnight.  The reagents were 
removed by suction and the resin was washed with DMF (3 × 1 mL) and MeOH (4 × 1 mL). 
A qualitative ninhydrin test was used to monitor the reaction by examining the remaining 
level of primary amino group.  After the quench of the primary amino group, half of the resin 
was washed with DMF (3 × 1 mL) to remove the methanol.  DMF solution (400 μL) 
containing TBTU (19 mg, 60 μmol), DIPEA (9 µL, 60 μmol) and hydrazine monohydrate (3 
µL, 60 μmol) was added to the resin.  After overnight coupling at room temperature, solvents 
and unreacted compounds were removed by suction, and the resin was washed with DMF (4 
× 1 mL) and MeOH (4 × 1 mL), respectively (Figure 53).  Again, the modification of the 
primary amine on the surface was confirmed by ninhydrin test. 
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Fig 53. Preparation of hydrazide resin 2.  
 
Preparation of cleavable linker 33 and spacer 34 
A cleavable linker is essential for recovering after the completion of the synthesis for 
further analysis.  Recently, Ole Hindsgaul and co-workers have developed a technique named 
solid-phase oligosaccharide tagging (SPOT), they showed that PEGA or CPG beads 
functionalized with hydroxylamine group could be used to capture oligosaccharide from 
solution (170).  In order to immobilize the oligosaccharide to the solid support, the authors 
synthesized a benzyl hydroxylamine capture groups attached through a cleavable ester 
linkage to a solid support, optionally through a spacer molecule.  The linker could be 
removed by treatment of base.  Based on this discovery, with the protocol and linker 33 
samples from Hindsgaul’s lab, our lab synthesized the same linker 33 and spacer 34 (Figure 
54) followed the procedures as reported (170). 
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Fig 54. Total Synthesis of cleavable Linker 33 and Spacer 34.  Panel A shows the total synthesis of linker 
33.  Panel B shows the total synthesis of spacer 34. 
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 Preparation of cleavable resin 3 
The linker 33 was installed on the solid support followed the literature (170).  Briefly, 
reactions were carried out in a 10 mL plastic column equipped with a scintered Teflon filter. 
Amino PEGA resin (50 mg) swelled in methanol was initially washed with DMF (3 × 1 mL) 
to ensure complete removal of the methanol. Linker 33 (22 mg, 50 μmol), TBTU (17 mg, 50 
μmol) and DIPEA (14 μL, 80 μmol) was mixed in 600 μL DMF and left for pre-activate for 5 
mins.  The solution mixture was then added to the resin.  After the beads were shaken at 
room temperature for 3 hours, the reagents were removed by suction and washed with 
CH2Cl2 (5 × 4 mL).  After confirming the occupation of primary amine was completed by A 
qualitative ninhydrin test, the Fmoc protection groups was removed by treatment with 20% 
piperidine in DMF for 1 hour at room temperature followed by extensive washes with DMF 
(5 × 4 mL) and CH2Cl2 (7 × 4 mL).  The resin was dried under high vacuum for 24 hours to 
give final PEGA resin 3. The linker could be removed by treatment of 1 M LiOH at room 
temperature for 1 hour (Figure 55). 
 
Installation of spacer  
The spacer 34 was installed on the solid support followed the literature (170).  The 
CPG resin (720 mg) was washed was washed with DMF (3 × 2 mL), swollen in MeOH (1 × 
10 mL), and then washed with DMF (3 x 1 mL), 10% DIPEA in DMF (3 × 1 mL) and DMF 
(3 × 1 mL).  The beads were incubated with a mixture of spacer 34 (60 mg, 0.12 mmol), 
TBTU (38 mg, 0.12 mmol) and DIPEA (20 µL, 0.12 mmol) in DMF (3 mL) overnight at 37 
°C. The resin was then washed with DMF (3 x 2 mL), CH2Cl2 (3 × 2 mL), and treated with 
50% Ac2O in pyridine for 30 min at room temperature to quench the remaining amino groups. 
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 A qualitative ninhydrin test was used to monitor the reaction by examining the remaining 
level of primary amino group.  The bead was then washed with CH2Cl2 (3 × 2 mL), DMF (3 
× 2mL), and CH2Cl2 (3 × 2 mL), respectively.  Removal of Boc groups was accomplished by 
treatment with 50% TFA in CH2Cl2 for 1 hour at room temperature and treated with 50% 
TFA in CH2Cl2 for 1 hour at room temperature.  The resin was washed with CH2Cl2 (3 × 2 
mL), DMF (3 × 2mL), respectively and the completion of the reaction was monitored by a 
qualitative ninhydrin test.  The coupling of spacer, Ac2O-pyriding, and TFA treatment were 
repeated to install the second spacer (Figure 56).  The linkers was linked to the spacer 
followed the same procedure as described above.  
 
 
 
 
Fig 55. Preparation of cleavable hydroxylamine resin 3.  After the installation of the linker 33, it could be 
cleaved by 1 M LiOH. 
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Fig 56. Installation of spacer 34. 
 
Immobilization of disaccharide to the solid support 
To immobilize the disaccharide to the solid support, we have examined the optimal 
conditions for the capture of disaccharide for two different resins.  Disaccharide (GlcUA-
AnMannose 2) was prepared from 10 mg heparosan, which was mixed with 140,000 cpm 
14C-labeled heparosan for calculation of coupling capacity. For PEGA beads, 1:1 DMF/H2O 
40 °C, and reaction for >12 h was found to be optimal.  Capping was achieved with 50 % 
acetic anhydride in MeOH (1 hour) and reduction was achieved with NaBH3CN (1 hour).  
For CPG beads, incubation overnight at 55 °C in aqueous phosphate buffer (NaH2PO4, pH 
5.0) proved to be optimal for the capture process (Figure 57).  The coupling capacity was 
calculated based on the incorporation of [14C] counts.  Coupling capacity for disaccharide 
was about 0.3 µg /mg (CPG) or 0.18 µg/mg (PEGA). 
 
 
 127
  
 
Fig 57. Immobilization of disaccharide to solid support. 
 
Solid phase KfiA assay 
A typical KfiA assay was in solution (400 µL) containing 25 mM Tris (pH 7.2), 10 
mM MnCl2, 1% triton, 0.1 mg KfiA and 35,000 cpm [3H]-UDP-GlcNAc.  The reaction 
mixture incubated with 4 µmol resin for overnight.  After washed with reaction buffer, the 
resin was taken to examine the remaining radioactivity.  The yield is calculated based on the 
incorporation of [3H] counts.  Although GlcNAc could be transferred to disaccharide 
immobilized on the solid phase, the yield is very low compare to solution phase.  PEGA is 
only about 1~2% yield while CPG has a better yield, which is about 28%.  This study 
indicated that solid phase synthesis might not be a viable approach to build up HS 
oligosaccharides. 
 
Section 3. Conclusion 
In this study, we successfully prepared three different resins which could immobilize 
disaccharide (GlcUA-AnMannose 2) into the solid support.  Although the disaccharide could 
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be immobilized to two different solid supports with reasonable capacity, and KfiA could 
successfully transfer a GlcNAc into the immobilized disaccharide, demonstrating the 
viability of solid phase HS synthesis, the low efficiency limited the further application of this 
technique to build up HS oligosaccharide, this either due to the reason that enzyme is 
entrapped at the solid surface or enzyme is difficult to recognize the substrate on the solid 
surface.  Further study need to investigate the possibility to synthesized the HS 
oligosaccharides on the solid surface. 
 
 Chapter VII CONCLUSION 
 
HS is a unique class of macromolecule that is widely expressed on the cell surface 
and in the extracellular matrix.  HS is involved in numerous biological processes, including 
blood coagulation, wound healing, embryonic development, regulation of tumor growth, and 
assisting viral and bacterial infections.  Thus, HS is a molecule with a high density of 
information and significant potential for therapeutic applications.  Heparin, an analog of HS, 
is a commonly used anticoagulant drug with annual sales close of up to $4 billion worldwide. 
However, the crisis of heparin drug in 2008 indicated that the heparin supply chain is 
vulnerable; a substitute for heparin with reduced side effects still remains a high priority. 
Understanding the mechanism employed by HS to regulate a specific biological process 
could improve the pharmacological drug properties of anticoagulant heparin and aid the 
development of HS or heparin-based therapeutic agents with anticancer and antiviral 
activities. 
The current study demonstrates the feasibility of a total synthesis of structurally 
defined HS oligosaccharides using a chemoenzymatic approach.  This method is capable of 
synthesizing oligosaccharides with different sulfation patterns and structures by transferring 
UDP-sugars onto an easily prepared disaccharide acceptor.  A key advancement enzymatic 
synthesis of these oligosaccharides involves the utilization of an unnatural UDP-donor that
 allows the controlled placement of GlcNS and GlcNAc residues throughout the 
oligosaccharide back bone. In Chapter III, an octasaccharide library with different 
  
 GlcNS/GlcNAc pattern was synthesized, proving the feasibility to control GlcNS/GlcNAc 
patterning.  In Chapter IV, hexasaccharides with different 6-O-sulfation patterns were 
synthesized, indicating the viability of this approach to control the subsequent positioning of 
O-sulfo groups through GlcNS/GlcNAc patterning and demonstrating that oligosaccharides 
synthesized via this approach can be recognized by the substrate specificity of the OSTs.  In 
Chapter V, we prepared different N-sulfo, O-sulfo deca, nonadeca and dodecasaccharide and 
found a novel dodecasaccharide with AT-binding activity. This study demonstrated the 
opportunity to prepare novel HS-based anticoagulant drugs as well as other HS-based 
therapeutic agents.  In Chapter VI, we examined the viability to build up HS oligosaccharide 
on a solid support. While we demonstrated the viability of solid phase HS synthesis, the low 
efficiency limited further application of this method. 
Further studies should focus on developing a more refined protocol to position the 
remaining modifications, such as 2-O- and 3-O-sulfation, as well as, incorporation of the 
IdoUA residue.  Also, improvement of binding affinity to AT may be possible by modifying 
HS sequence through the appropriate placement of GlcNAc residues.  Therefore, several 
dodecasaccharides with different GlcNS and GlcNAc patterning should be prepared.  
Furthermore, the tagged oligosaccharides of different sizes will be prepared to discover the 
minimum size of tagged oligosaccharides required to exhibit both anti-IIa and anti-Xa 
activities. 
While this method is fully capable of synthesizing large libraries of diverse HS 
oligosaccharide structures, it is currently limited by the time and effort required for the full 
structural characterization of the resulting oligosaccharide products.  Advances in analytical 
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methods, especially MS and MS/MS will be required to expand our synthesis to a greater and 
more structurally complex variety of defined oligosaccharide structures.   
Overall, this dissertation advanced our understanding of HS biosynthesis.  Most 
importantly, the results will not only allow us to investigate novel synthesis of anticoagulant 
drugs but also lead to a general method for preparation of structurally more defined HS 
structures with various other biological functions and help develop novel heparin/HS based 
therapeutic agents. 
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